

THE JOURNAL OF CLINICAL PSYCHIATRY

Author Index to Volume 72: January 2011 Through December 2011

- Abel KM see Laursen TM
- Addington DE, Mohamed S, Rosenheck RA, Davis SM, Stroup TS, McEvoy JP, Swartz MS, Lieberman JA. Impact of second-generation antipsychotics and perphenazine on depressive symptoms in a randomized trial of treatment for chronic schizophrenia. Jan 75–80
- Adler LA, Barkley RA, Newcorn JH. Performance improvement CME: adult ADHD. Apr e15
- Adler LA, Newcorn JH. Administering and evaluating the results of the adult ADHD Self-Report Scale (ASRS) in adolescents. June e20
- Adler LA, Newcorn JH. Assessing adolescents using ADHD rating scales. May e17
- Agartz I see Steen NE
- Agid O, Arenovich T, Sajeev G, Zipursky RB, Kapur S, Fousias G, Remington G. Algorithm-based approach to first-episode schizophrenia: response rates over 3 prospective antipsychotic trials with a retrospective data analysis. Nov 1439–1444
- Ahn W-k see Rottman BM
- Aitchison KJ see Mondelli V; Uher R
- Alberich S see González-Pinto A
- Albert MS see Reiman EM
- Alder J see Wirz-Justice A
- Alegria M see Polo AJ
- Alesci S see Bonne O
- Alexopoulos GS. Pharmacotherapy for late-life depression. Jan e04
- Allen JD see Kung S
- Allen MH, Feifel D, Lesem MD, Zimbroff DL, Ross R, Munzar P, Spkyer DA, Cassella JV. Efficacy and safety of loxapine for inhalation in the treatment of agitation in patients with schizophrenia: a randomized, double blind, placebo-controlled trial. Oct 1313–1321
- Almás B see Steen NE
- Alonso M see González-Pinto A
- Alonso P see Labad J
- Altamura AC see Glick ID
- Altoè G see Moscardino U
- Altshuler LL see Gitlin MJ; Suri R
- Álvarez E see Portella MJ
- Ameral VE see Tedeschi E
- Amminger GP see Yung AR
- Amoyal NA see Gould NF
- Ancelin M-L see Chaudieu I
- Andel R see Van Dorn RA
- Anderson-Hunt M see Berk M
- Andrade C. Odd odds [letter with reply]. Nov 1558–1559
- Andreassen OA see Steen NE
- Andresescu C, Glick RM, Emeremni CA, Houck PR, Mulsant BH. Acupuncture for the treatment of major depressive disorder: a randomized controlled trial. Aug 1129–1135
- Angermeier T see Hummel J
- Annunziato RA see Shemesh E
- Annweiler C see Richard-Devantoy S
- Ansell EB see Yen S
- Anway SD see Karayal ON
- Appleby L see Laursen TM
- Aquino A see Suri R
- Arango C see Nuevo R
- Araya S see Usall J
- Arbuckle M see Harding KJK
- Archambeau OG, Elhai JD, Frueh BC. Definition of psychological trauma and threshold for functional impairment in PTSD [letter]. Mar 416–417
- Ardèvol M see Diez-Quevedo C
- Arenovich T see Agid O
- Arnold LE see Axelson DA; Frazier TW
- Artigas F see Portella MJ
- Asarow JR see Vitiello B
- Ashih H see Desseilles M
- Asnis GM see Fava M
- Athanasiosu MC, Dettling M, Cascorbi I, Mosyagin I, Salisbury BA, Pierz KA, Zou W, Whalen H, Malhotra AK, Lencz T, Gerson SL, Kane JM, Reed CR. Candidate gene analysis identifies a polymorphism in *HLA-DQB1* associated with clozapine-induced agranulocytosis. Apr 458–463
- Athanasiosu M see Khan A
- Axelson DA, Birmaher B, Findling RL, Fristad MA, Kowatch RA, Youngstrom EA, Arnold LE, Goldstein BI, Goldstein TR, Chang KD, DeBello MP, Ryan ND, Diler RS. Concerns regarding the inclusion of temper dysregulation disorder with dysphoria in the *Diagnostic And Statistical Manual of Mental Disorders*, Fifth Edition [commentary]. Sept 1257–1262
- Axelson DA see Frazier TW
- Ayuso-Mateos JL see Nuevo R
- Baca-Garcia E see Dervic K
- Bader A see Wirz-Justice A
- Baer L see Chen JA; Posternak MA
- Baghai TC, Varallo-Bedarida G, Born C, Häfner S, Schüle C, Eser D, Rupprecht R, Bondy B, von Schacky C. Major depressive disorder is associated with cardiovascular risk factors and low omega-3 index. Sept 1242–1247
- Bagley SC. Predicting suicide attempt risk: logistic regression requires large sample sizes [letter with reply]. Dec 1698
- Bai YM, Lin C-C, Chen J-Y, Chen TT, Su T-P, Chou P. Association of weight gain and metabolic syndrome in patients taking clozapine: an 8-year cohort study. June 751–756
- Bai YM, Lin C-C, Chen TT, Su T-P. Reply to Suzuki T: Metabolic syndrome in inpatients treated with clozapine [letter]. June 873–874
- Bak M see Lataster J
- Baker K see Yung AR
- Baldessarini RJ. Suicidal risk during antidepressant treatment [letter with reply]. May 722
- Baldessarini RJ see Salvatore P
- Ball DE see Signorovitch J
- Ballesteros J see Portella MJ
- Baltuch GH see Cristancho P
- Bandinelli S see Vogelzangs N
- Barbee JG, Thompson TR, Jamhour NJ, Stewart JW, Conrad EJ, Reimherr FW, Thompson PM, Shelton RC. Double-blind placebo-controlled trial of lamotrigine as an antidepressant augmentation agent in treatment-refractory unipolar depression. Oct 1405–1412
- Barbeito S see González-Pinto A
- Barkhof F see Oudega ML
- Barkley RA see Adler LA
- Barrett EA see Steen NE
- Barton D. Review of Bauer MS: *A Mind Apart: Poems of Melancholy, Madness, and Addiction*. Apr 570–571
- Bastani B see Fava M
- Batzar E see Karayal ON
- Bauer M see Strech D
- Beauchet O see Richard-Devantoy S
- Beblo I see Terfehr K
- Becker MA see Boaz TL; Van Dorn RA
- Beekman ATF see Lamers F; Oudega ML; Vogelzangs N; Wiersma JE
- Benedetti F see Wirz-Justice A
- Ben-Hamadi R see Signorovitch J
- Bentley KH see Iovieno N
- Beresin EV see Sadhu JM
- Berg JP see Steen NE
- Berger G see Yung AR
- Bergink V, Lambertse-van den Berg MP, Kooregevel KM, Kupka R, Kushner SA. First-onset psychosis occurring in the postpartum period: a prospective cohort study. Nov 1531–1537
- Bergmann A see Buerger K
- Berk M, Munib A, Dean O, Malhi GS, Kohlmann K, Schapkaitz I, Jeavons S, Katz F, Anderson-Hunt M, Conus P, Hanna B, Otmar R, Ng F, Copolov DL, Bush AI. Qualitative methods in early-phase drug trials: broadening the scope of data and methods from an RCT of *N*-acetylcysteine in schizophrenia. July 909–913
- Berk M see Stafford L
- Berlin HA, Koran LM, Jenike MA, Shapira NA, Chaplin W, Pallanti S, Hollander E. Double-blind, placebo-controlled trial of topiramate augmentation in treatment-resistant obsessive-compulsive disorder. May 716–721
- Berman RM see Weisler RH
- Berthele A see Hamann J
- Bhagwagar Z see Saricicek A
- Bhattaram A see Laughren TP
- Bialobos S see Gerardin P
- Biederman J, Fried R, Petty CR, Wozniak J, Doyle AE, Henin A, Corkum L, Claudat K, Faraone SV. Cognitive development in adults with attention-deficit/hyperactivity disorder: a controlled study in medication-naive adults across the adult life cycle. Jan 11–16
- Biederman J see Hua LL
- Biggs A see Cornwell BR
- Birmaher B see Axelson DA; Frazier TW; Vitiello B
- Birmes P see Chaudieu I
- Birnbaum H see Signorovitch J

- Bitter I see Volavka J
- Bitzer J see Wirz-Justice A
- Blacker D see Reiman EM
- Blair SN see Trivedi MH
- Blanco C see Comer JS; Pickering RP; Polo AJ
- Blennow K see Buerger K
- Blizotes MM see Calarge CA
- Blom JD see Daalman K
- Blum JI see Lawson EA
- Blumberg HP see Saricicek A
- Boaz TL, Constantine RJ, Robst J, Becker MA, Howe AM. Risperidone long-acting therapy prescribing patterns and their impact on early discontinuation of treatment in a large Medicaid population. Aug 1079–1085
- Boaz TL see Van Dorn RA
- Bobo WV see Meltzer HY
- Bodeau N see Gerardin P
- Boelhouwer IG see Vogelzangs N
- Bokde ALW see Frodl T
- Boks MPM see Daalman K
- Bonaccorso S see Meltzer HY
- Bondy B see Baghai TC
- Bonne O, Gill JM, Luckenbaugh DA, Collins C, Owens MJ, Alesci S, Neumeister A, Yuan P, Kinkead B, Manji HK, Charney DS, Vythilingam M. Corticotropin-releasing factor, interleukin-6, brain-derived neurotrophic factor, insulin-like growth factor-1, and substance P in the cerebrospinal fluid of civilians with posttraumatic stress disorder before and after treatment with paroxetine. Aug 1124–1128
- Born C see Baghai TC
- Bosch P see van den Noort M
- Bourgeois JA, Seritan AL, Casillas EM, Hessel D, Schneider A, Yang Y, Kaur I, Cogswell JB, Nguyen DV, Hagerman RJ. Lifetime prevalence of mood and anxiety disorders in fragile X premutation carriers. Feb 175–182
- Bowden CL see Brooks JO III
- Bowers WA. Review of Safer DL, Telch CF, Chen EY: *Dialectical Behavior Therapy for Binge Eating and Bulimia*. Mar 421–422
- Boyd RC, Joe S, Michalopoulos L, Davis E, Jackson JS. Prevalence of mood disorders and service use among US mothers by race and ethnicity: results from the National Survey of American Life. Nov 1538–1545
- Bradley B, DeFife JA, Guarnaccia C, Phifer J, Fani N, Ressler KJ, Westen D. Emotion dysregulation and negative affect: association with psychiatric symptoms. May 685–691
- Braga RJ see Gilbert AM
- Brähler E see Timpano KR
- Brandes M see Pollack MH
- Brecht S, Desaijah D, Marechal ES, Santini AM, Podhorna J, Guelfi JD. Efficacy and safety of duloxetine 60 mg and 120 mg daily in patients hospitalized for severe depression: a double-blind randomized trial. Aug 1086–1094
- Brent DA see Dervic K; Vitiello B
- Britton A see Nabi H
- Bromet EJ see Ruggero CJ
- Brooks JO III, Goldberg JF, Ketter TA, Miklowitz DJ, Calabrese JR, Bowden CL, Thase ME. Safety and tolerability associated with second-generation antipsychotic polytherapy in bipolar disorder: findings from the Systematic Treatment Enhancement Program for Bipolar Disorder. Feb 240–247
- Brower KJ, McCammon RJ, Wojnar M, Ilgen MA, Wojnar J, Valenstein M. Prescription sleeping pills, insomnia, and suicidality in the National Comorbidity Survey Replication. Apr 515–521
- Brown FW. Review of Katon W, Maj M, Sartorius N (eds): *Depression and Diabetes*. Aug 1159–1160
- Brückmann H see Frodl T
- Bryant RA. Acute stress disorder as a predictor of posttraumatic stress disorder: a systematic review. Feb 233–239
- Buckley PF see Kane JM
- Buerger K, Uspenskaya O, Hartmann O, Hansson O, Minthon L, Blennow K, Moeller H-J, Teipel SJ, Ernst A, Bergmann A, Hampel H. Prediction of Alzheimer's disease using midregional proadrenomedullin and midregional proatrial natriuretic peptide: a retrospective analysis of 134 patients with mild cognitive impairment. Apr 556–563
- Bühner M see Hamann J
- Burdick KE see Gilbert AM
- Bush AI see Berk M
- Busschbach JJV see Soeteman DI
- Bystritsky AM see Shiovitz TM; Stein MB
- Calabrese JR, Prescott M, Tamburrino M, Liberzon I, Slembariski R, Goldmann E, Shirley E, Fine T, Goto T, Wilson K, Ganocy S, Chan P, Serrano MB, Sizemore J, Galea S. PTSD comorbidity and suicidal ideation associated with PTSD within the Ohio Army National Guard. Aug 1072–1078
- Calabrese JR see Brooks JO III; Gao K; Kemp DE; Muzina DJ
- Calarge CA, Ellingrod VL, Zimmerman B, Blizotes MM, Schlechte JA. Variants of the serotonin transporter gene, selective serotonin reuptake inhibitors, and bone mass in risperidone-treated boys: a reanalysis of data from a cross-sectional study with emphasis on pharmacogenetics. Dec 1685–1690
- Campbell EC see Caroff SN
- Campbell-Sills L see Stein MB
- Capello F see Moscardino U
- Carballo JJ see Dervic K
- Carlson BX see Weisler RH
- Carlson GA see Ruggero CJ
- Carmody TJ see Trivedi MH
- Caroff SN, Davis VG, Miller DD, Davis SM, Rosenheck RA, McEvoy JP, Campbell EC, Saltz BL, Riggio S, Chakos MH, Swartz MS, Keefe RSE, Stroup TS, Lieberman JA, CATIE Investigators. Treatment outcomes of patients with tardive dyskinesia and chronic schizophrenia. Mar 295–303
- Caroff SN see Gurrera RJ
- Carpenter DJ, Fong R, Kraus JE, Davies JT, Moore C, Thase ME. Meta-analysis of efficacy and treatment-emergent suicidality in adults by psychiatric indication and age subgroup following initiation of paroxetine therapy: a complete set of randomized placebo-controlled trials. Nov 1503–1514
- Carpenter DJ, Fong R, Kraus JE, Davies JT, Moore C, Thase ME. Reply to Andrade C: Odd odds [letter]. Nov 1559
- Carroll BT see Gurrera RJ
- Carson WH see Marcus RN
- Carter T see Compton MT
- Cascorbi I see Athanasiou MC
- Casillas EM see Bourgeois JA
- Cassella JV see Allen MH
- Castellvi P see Diez-Quevedo C
- CATIE Investigators see Caroff SN
- Cattaneo A see Mondelli V
- Cavallo DA see Liu TC
- Cerimele JM. Integrated medical care for patients with bipolar disorder: who will be the principal physician? [letter] May 723–724
- Chakos MH see Caroff SN
- Chan H-Y, Gau SS-F, Chang C-J. Reply to Peritogiannis V: Emerging role of atypical antipsychotics in the treatment of tardive dyskinesia induced by other atypical antipsychotics [letter]. July 1016–1017
- Chan P see Calabrese JR
- Chan PK see Muzina DJ
- Chan RCK see Zhang W-F
- Chandler K see Van Dorn RA
- Chang C-J see Chan H-Y
- Chang C-L see Kuo C-J
- Chang KD see Axelson DA
- Chang TE see Desseilles M
- Chaplin W see Berlin HA
- Chappell PB see Sachs GS
- Charney DS see Bonne O; Murrough JW
- Chatterji S see Nuevo R
- Chaudieu I, Norton J, Ritchie K, Birmes P, Vaiva G, Ancelin M-L. Late-life health consequences of exposure to trauma in a general elderly population: the mediating role of reexperiencing posttraumatic symptoms. July 929–935
- Chelminski I see Zimmerman M
- Chen C-C see Kuo C-J
- Chen C-N see Polo AJ
- Chen JA, Papakostas GI, Youn SJ, Baer L, Clain AJ, Fava M, Mischoulon D. Association between patient beliefs regarding assigned treatment and clinical response: reanalysis of data from the *Hypericum* Depression Trial Study Group. Dec 1669–1676
- Chen J-Y see Bai YM
- Chen TT see Bai YM
- Chen WJ see Kuo C-J
- Chen Y see Meltzer HY
- Chen Y-F see Khin NA
- Chen Y-Y, Yip PSF. Suicide sex ratios after the inception of charcoal-burning suicide in Taiwan and Hong Kong [letter]. Apr 566–567
- Cheng Q, Fu K-w, Yip PSF. Comparative study of online suicide-related information in Chinese and English. Mar 313–319
- Chiles C. Review of Sadock BJ, Sadock VA: *Kaplan & Sadock's Pocket Handbook of Clinical Psychiatry, 5th ed*. Sept 1288–1289
- Chou K-L, Liang K, Mackenzie CS. Binge drinking and Axis I psychiatric disorders in community-dwelling middle-aged and older adults: results from the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC). May 640–647

- Chou K-L, Liang K, Sareen J.** Association between social isolation and *DSM-IV* mood, anxiety, and substance use disorders: wave 2 of the National Epidemiologic Survey on Alcohol and Related Conditions. Nov 1468–1476
- Chou K-L, Mackenzie CS, Liang K, Sareen J.** Three-year incidence and predictors of first-onset of *DSM-IV* mood, anxiety, and substance use disorders in older adults: results from wave 2 of the National Epidemiologic Survey on Alcohol and Related Conditions. Feb 144–155
- Chou P** see **Bai YM**
- Chou SP** see **Pickering RP**
- Church TS** see **Trivedi MH**
- Citrome L.** Iloperidone: a clinical overview. Suppl 1, 19–23
- Citrome L.** Likelihood to be helped or harmed can assist in clinical decision-making [letter with reply]. Feb 261–262
- Citrome L.** Number needed to treat: what it is and what it isn't, and why every clinician should know how to calculate it [ASCP Corner]. Mar 412–413
- Clain AJ** see **Chen JA**
- Clarke G** see **Vitiello B**
- Claudat K** see **Biederman J**
- Clayton PJ.** Back to “normal bereavement” [letter with reply]. Feb 260
- Cloutier G** see **Normand E**
- Cobo J** see **Usall J**
- Cogswell JB** see **Bourgeois JA**
- Cohen A** see **Gurrera RJ**
- Cohen D** see **Gerardin P**
- Cohen LJ** see **Katz C**
- Cohen LS** see **Suri R**
- Cohen R** see **Hamann J**
- Cohen-Mansfield J, Marx MS, Thein K, Dakheel-Ali M.** Impact of stimuli on affect in persons with dementia. Apr 480–486
- Collins C** see **Bonne O**
- Comer JS, Blanco C, Hasin DS, Liu S-M, Grant BF, Turner JB, Olsson M.** Health-related quality of life across the anxiety disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC). Jan 43–50
- Comijs HC** see **Lamers F; Oudega ML**
- Compton MT, Gordon TL, Goulding SM, Esterberg ML, Carter T, Leiner AS, Weiss PS, Druss BG, Walker EF, Kaslow NJ.** Patient-level predictors and clinical correlates of duration of untreated psychosis among hospitalized first-episode patients. Feb 225–232
- Compton MT, Gordon TL, Weiss PS, Walker EF.** “Doses” of initial, untreated hallucinations and delusions: a proof-of-concept study of enhanced predictors of first-episode symptomatology and functioning relative to duration of untreated psychosis. Nov 1487–1493
- Conrad EJ** see **Barbee JG**
- Conroy CM** see **Muzina DJ**
- Constantine RJ** see **Boaz TL**
- Conus P** see **Berk M**
- Conwell Y** see **Kuo C-J**
- Cooper J** see **Oude Voshaar RC**
- Copopol DL** see **Berk M**
- Corbin J-F** see **Normand E**
- Corkum L** see **Biederman J**
- Cornwell BR, Heller R, Biggs A, Pine DS, Grillon C.** Becoming the center of attention in social anxiety disorder: startle reactivity to a virtual audience during speech anticipation. July 942–948
- Correll CU.** Addressing adverse effects of antipsychotic treatment in young patients with schizophrenia. Jan e01
- Correll CU.** Psychobiology and psychosocial functioning of schizoaffective disorder. Feb e05
- Correll CU.** Safety and tolerability of antipsychotic treatment in young patients with schizophrenia. Aug e26
- Correll CU.** What are we looking for in new antipsychotics? Suppl 1, 9–13
- Correll CU, Kratochvil CJ, March JS.** Developments in pediatric psychopharmacology: focus on stimulants, antidepressants, and antipsychotics. May 655–670
- Correll CU, Lops JD, Figen V, Malhotra AK, Kane JM, Manu P.** QT interval duration and dispersion in children and adolescents treated with ziprasidone. June 854–860
- Correll CU** see **Glick ID; Kane JM; Manu P; Nielsen J**
- Corruble E, Falissard B, Gorwood P.** Is *DSM-IV* bereavement exclusion for major depression relevant to treatment response? a case-control, prospective study. July 898–902
- Corruble E, Falissard B, Gorwood P.** Reply to Wakefield JC: Treatment outcome for bereavement-excluded depression: results of the study by Corruble et al are not what they seem [letter]. Aug 1155–1156
- Corry NH** see **Gould NF**
- Corya S** see **Zanarini MC**
- Coryell WH** see **Leon AC**
- Costa J** see **Diez-Quevedo C**
- Cotter G** see **Shemesh E**
- Cox B** see **Pagura J**
- Craig TJ** see **Smith EG**
- Craske MG** see **Stein MB**
- Crawford C** see **Davidson JRT**
- Crisanti AS, Frueh G, Gundaya DM, Salvail FR, Triffleman EG.** Ethnoracial disparities in sexual assault among Asian Americans and Native Hawaiians/other Pacific Islanders. June 820–826
- Cristancho MA** see **Cristancho P**
- Cristancho P, Cristancho MA, Baltuch GH, Thase ME, O'Reardon JP.** Effectiveness and safety of vagus nerve stimulation for severe treatment-resistant major depression in clinical practice after FDA approval: outcomes at 1 year. Oct 1376–1393
- Croarkin PE** see **Wall CA**
- Cruz N, Vieta E.** Antidepressants in acute bipolar depression: an inconclusive meta-analysis [letter with reply]. Mar 415–416
- Csernansky JG** see **Glick ID**
- Culpepper L.** Presentation and diagnosis of fibromyalgia. Dec e38
- Culpepper L.** Prevalence and impact of ADHD in college students. Sept e30
- Culpepper L.** Recognizing and diagnosing ADHD in college students. Oct e33
- Culpepper L.** Understanding the burden of depression. June e19
- Cutler AJ** see **Khan A**
- Czobor P** see **Krakowski MI; Volavka J**
- Daalman K, Boks MPM, Diederer KJM, de Weijer AD, Blom JD, Kahn RS, Sommer IEC.** Same or different? a phenomenological comparison of auditory verbal hallucinations in healthy and psychotic individuals. Mar 320–325
- Dakheel-Ali M** see **Cohen-Mansfield J**
- Dalrymple K** see **Zimmerman M**
- Damian M** see **Hausner L**
- Daniel DG** see **Kane JM**
- Darbois Y** see **Gerardin P**
- Davidson JRT, Crawford C, Ives JA, Jonas WB.** Homeopathic treatments in psychiatry: a systematic review of randomized placebo-controlled studies. June 795–805
- Davies JT** see **Carpenter DJ**
- Davis E** see **Boyd RC**
- Davis JM** see **Glick ID**
- Davis SM** see **Addington DE; Caroff SN**
- Davis VG** see **Caroff SN**
- Dawson DA** see **Pickering RP**
- Dazzan P** see **Mondelli V**
- Dean O** see **Berk M**
- DeBar L** see **Vitiello B**
- Deberdt W** see **Zanarini MC**
- de Craen AJM** see **Oudega ML**
- de Diego-Adeliño J** see **Portella MJ**
- DeFife JA** see **Bradley B**
- de Haan L** see **Lataster J**
- DelBello MP** see **Axelson DA**
- Delespaul PAEG** see **Lataster J**
- Delieu J** see **Lepping P**
- Delimon J** see **Soeteman DI**
- Demeter CA** see **Frazier TW**
- Derks EM** see **Volavka J**
- DeRoos F** see **Gurrera RJ**
- Dervic K, Carballo JJ, Baca-Garcia E, Galfalvy HC, Mann JJ, Brent DA, Oquendo MA.** Moral or religious objections to suicide may protect against suicidal behavior in bipolar disorder. Oct 1390–1396
- Desai RA** see **Liu TC**
- Desaiah D** see **Brecht S**
- Desmarais SL** see **Van Dorn RA**
- Desseilles M, Witte J, Chang TE, Iovieno N, Dording CM, Ashih H, Nyer M, Freeman MP, Fava M, Mischoulon D.** Assessing the adequacy of past antidepressant trials: a clinician's guide to the antidepressant treatment response questionnaire [ASCP Corner]. Aug 1152–1154
- Detke HC** see **Zanarini MC**
- Detting M** see **Athanasiou MC**
- Deuschle M** see **Hummel J**
- de Weijer AD** see **Daalman K**
- Diago M** see **Diez-Quevedo C**
- Dickerson J** see **Vitiello B**
- Diederer KJM** see **Daalman K**
- Diez-Quevedo C, Masnou H, Planas R, Castellví P, Giménez D, Morillas RM, Martín-Santos R, Navinés R, Solà R, Giner P, Ardèvol M, Costa J, Diago M, Pretel J.** Prophylactic treatment with escitalopram of pegylated interferon alfa-2a-induced depression in hepatitis C: a 12-week, randomized, double-blind, placebo-controlled trial. Apr 522–528
- Di Forti M** see **Mondelli V**
- Diler RS** see **Axelson DA**
- Dinh PV** see **Laughren TP**

- Dinstein Y see Nacasch N
 Diplich D see Hamann J
 Dodge KA. Review of Reynolds CR, Fletcher-Janzen E (eds): *Handbook of Clinical Child Neuropsychology*, 3rd ed. May 726
 Dommergues M see Gerardin P
 Donoho DA see Lawson EA
 Dording CM see Desseilles M
 do Rosário MC see Torres AR
 Doshi JA see Olsson M
 Doty L see George DT
 Dowd SM see Wall CA
 Doyle AE see Biederman J
 Driessen M see Terfehr K
 Druss BG see Compton MT; Pagura J
 Dunlop BW see Rakofsky JJ
 Dunn AL see Trivedi MH
 Dunner DL. Review of Mrazek DA: *Psychiatric Pharmacogenomics*. May 727
 Dupuy JM see Sachs GS
 Earnest CP see Trivedi MH
 Edelen MO see Yen S
 Edlund MJ see Fortney JC
 Eickhoff M see Gaebel W
 Eikelenboom P see Oudega ML
 Elhai JD see Archambeau OG
 Elizagarate E see Lertxundi U
 Ellingrod VL see Calarge CA
 Elliott RL. Does combat trauma cause a majority of PTSD symptoms in combat veterans? [letter with reply] May 724–725
 Ellis SP see Sublette ME
 Ellison JM. Review of Depp CA, Jeste DV (eds): *Successful Cognition and Emotional Aging*. May 726–727
 Emeremni CA see Andrescu C
 Empana J-P see Nabi H
 Emslie GJ see Vitiello B; Wall CA
 Endicott J see Leon AC
 Ernst A see Buerger K
 Ernst E see Lee MS
 Eronen M see Tchoukhine E
 Eser D see Baghai TC
 Esterberg ML see Compton MT
 Eudicone JM see Weisler RH
 EUFEST Study Group see Volavka J
 Evans SJW see Petersen I
 Evins AE see Iovieno N
 Exner C see Timpano KR
 Falissard B see Corruble E
 Fan X, Liu EY, Hoffman VP, Potts AJ, Sharma B, Henderson DC. Triglyceride/high-density lipoprotein cholesterol ratio: a surrogate to predict insulin resistance and low-density lipoprotein cholesterol particle size in nondiabetic patients with schizophrenia. June 806–812
 Fang Y see Gao K
 Fani N see Bradley B
 Faraone SV see Biederman J; Waxmonsky JG
 Farber SB see Swardfager W
 Farmer A see Uher R
 Fauerbach JA see Gould NF
 Fava GA see Grandi S
 Fava M, Asnis GM, Shrivastava RK, Lydiard B, Bastani B, Sheehan DV, Roth T. Improved insomnia symptoms and sleep-related next-day functioning in patients with comorbid major depressive disorder and insomnia following concomitant zolpidem extended-release 12.5 mg and escitalopram treatment: a randomized controlled trial. July 914–928
 Fava M, Schaefer K, Huang H, Wilson A, Iosifescu DV, Mischoulon D, Wessel TC. Post hoc analysis of the effect of nightly administration of eszopiclone and a selective serotonin reuptake inhibitor in patients with insomnia and anxious depression. Apr 473–479
 Fava M, Shelton RC, Zajecka JM. Evidence for the use of L-methylfolate combined with antidepressants in MDD. Aug e25
 Fava M see Chen JA; Desseilles M; Posternak MA; Tedeschini E; Zisook S
 Fazel S see Jones RM
 Feaganes JR see Shemesh E
 Feifel D see Allen MH
 Fein E see Gao K
 Feingold A see Remington G
 Fernando SC see Terfehr K
 Ferrão YA see Torres AR
 Ferrucci L see Vogelzangs N
 Fiedorowicz JG see Leon AC
 Figen V see Correll CU
 Findling RL see Axelson DA; Frazier TW; Marcus RN
 Fine T see Calabrese JR
 First MB. Problematic DSM-5 personality disorders proposal: options for plan B [commentary]. Oct 1341–1343
 First MB see Wakefield JC
 Fishman SM. Strategies for selecting treatment and mitigating risk in patients with chronic pain. Jan e02
 Fleischhacker WW see Volavka J
 Flood P see Rodriguez CI
 Foa EB see Nacasch N
 Fong R see Carpenter DJ
 Fontenelle LF see Torres AR
 Fortney JC, Pyne JM, Edlund MJ, Stecker T, Mittal D, Robinson DE, Henderson KL. Reasons for antidepressant nonadherence among veterans treated in primary care clinics. June 827–834
 Fortney JC see Mittal D
 Fossom L see Laughren TP
 Foster JA see Lokuge S
 Fostick L see Nacasch N
 Fousias G see Agid O
 Fraguas D see Nuevo R
 Francey SM see Yung AR
 Francis A see Gurrera RJ
 Frasure-Smith N see Lespérance F
 Frazier TW, Youngstrom EA, Horwitz SM, Demeter CA, Fristad MA, Arnold LE, Birmaher B, Kowatch RA, Axelson D, Ryan N, Gill MK, Findling RL. Relationship of persistent manic symptoms to the diagnosis of pediatric bipolar spectrum disorders. June 846–853
 Freeman AM III. Review of Summers RF, Barger JP: *Psychodynamic Therapy: A Guide to Evidence-Based Practice*. July 1018–1019
 Freeman BW. Review of Gutheil TG: *The Psychiatrist as Expert Witness*, 2nd ed. July 1019–1020
 Freeman MP. Antidepressant medication treatment during pregnancy: prevalence of use, clinical implications, and alternatives. July 977–978
 Freeman MP. Biopsychosocial vulnerabilities in women [introduction]. Nov 1529–1530
 Freeman MP, Rapaport MH. Omega-3 fatty acids and depression: from cellular mechanisms to clinical care [ASCP Corner]. Feb 258–259
 Freeman MP see Desseilles M; Gelenberg AJ
 Freudenreich O see Goff DC
 Frey BN see Kapczinski F; Lokuge S
 Fried R see Biederman J
 Friedman SH, Resnick PJ. Child murder and mental illness in parents: implications for psychiatrists [commentary]. May 587–588
 Frisch U see Wirz-Justice A
 Fristad MA see Axelson DA; Frazier TW
 Frodl T, Scheurecker J, Schoepf V, Linn J, Koutsouleris N, Bokde ALW, Hampel H, Möller H-J, Brückmann H, Wiesmann M, Meisenzahl E. Different effects of mirtazapine and venlafaxine on brain activation: an open randomized controlled fMRI study. Apr 448–457
 Frölich L see Hausner L
 Frucht S see Gurrera RJ
 Frueh BC see Archambeau OG
 Frueh C see Crisanti AS
 Frye MA, Ha K, Kanba S, Kato T, McElroy SL, Özderem A, Vázquez G, Vieta E. International Consensus Group on Depression Prevention in Bipolar Disorder [commentary]. Oct 1295–1310
 Fu K-w see Cheng Q
 Fujita H see Watanabe N
 Furukawa TA see Watanabe N
 Gaebel W, Riesbeck M, Wölwer W, Klimke A, Eickhoff M, von Wilmsdorff M, Lemke M, Heuser I, Maier W, Huff W, Schmitt A, Sauer H, Riedel M, Klingberg S, Köpcke W, Ohmann C, Möller H-J, German Study Group on First-Episode Schizophrenia. Relapse prevention in first-episode schizophrenia—maintenance vs intermittent drug treatment with prodrome-based early intervention: results of a randomized controlled trial within the German Research Network on Schizophrenia. Feb 205–218
 Gaebel W, Riesbeck M. Reply to Suzuki T: Risks of intermittent antipsychotic treatment in schizophrenia [letter]. Jan 114–115
 Galea S see Calabrese JR
 Galfalvy HC see Dervic K
 Galin A see Gerardin P
 Gallego JA, Robinson DG, Sevy SM, Napolitano B, McCormack J, Lesser ML, Kane JM. Time to treatment response in first-episode schizophrenia: should acute treatment trials last several months? Dec 1691–1696
 Gallipoli S see Khan A
 Galper DI see Trivedi MH
 Galynker II see Katz C
 Ganocy SJ see Calabrese JR, Gao K, Muzina DJ
 Ganoczy D see Smith EG
 Gao K, Kemp DE, Calabrese JR. Reply to Citrome L: Likelihood to be helped or harmed can assist in clinical decision-making [letter]. Feb 262

- Gao K, Kemp DE, Fein E, Wang Z, Fang Y, Ganocy SJ, Calabrese JR. Number needed to treat to harm for discontinuation due to adverse events in the treatment of bipolar depression, major depressive disorder, and generalized anxiety disorder with atypical antipsychotics. Aug 1063–1071
- Gao K see Muzina DJ
- Garno JL see Gilbert AM
- Garré J-B see Richard-Devantoy S
- Gau SS-F see Chan H-Y
- Gaumond I see Normand E
- Gaynes BN see Trivedi MH
- Geant AL see Sublette ME
- Gelenberg AJ, Freeman MP. Our sincere thanks [editorial]. Jan 6–10
- George DT, Phillips MJ, Lifshitz M, Lionetti TA, Spero DE, Ghassemzadeh N, Doty L, Umhau JC, Rawlings RR. Fluoxetine treatment of alcoholic perpetrators of domestic violence: a 12-week, double-blind, randomized, placebo-controlled intervention study. Jan 60–65
- Gerardin P, Wendland J, Bodeau N, Galin A, Bialobos S, Tordjman S, Mazet P, Darbois Y, Nizard J, Dommergues M, Cohen D. Depression during pregnancy: is the developmental impact earlier in boys? a prospective case-control study. Mar 378–387
- German Study Group on First-Episode Schizophrenia see Gaebel W
- Gerretsen P, Pollock BG. Rediscovering adverse anticholinergic effects [ASCP Corner]. June 869–870
- Gerson SL see Athanasiou MC
- Ghaemi SN. Reply to Rasmussen KG: Do antidepressants really beget more depressive episodes? [letter] Jan 116
- Ghassemzadeh N see George DT
- Gibbons RD see Woo J-M
- Gilbert AM, Braga RJ, Burdick KE. Reply to Bagley SC: Predicting suicide attempt risk: logistic regression requires large sample sizes [letter]. Dec 1698
- Gilbert AM, Garno JL, Braga RJ, Shaya Y, Goldberg TE, Malhotra AK, Burdick KE. Clinical and cognitive correlates of suicide attempts in bipolar disorder: is suicide predictable? Aug 1027–1033. Correction, Dec 1698
- Gilbert RE see Petersen I
- Gilbertson MW, Pitman RK. Reply to Elliott RL: Does combat trauma cause a majority of PTSD symptoms in combat veterans? [letter] May 725
- Gill JM see Bonne O
- Gill MK see Frazier TW
- Gilles M see Hummel J
- Gillihan SJ, Parens E. Should we expect “neural signatures” for DSM diagnoses? Oct 1383–1389
- Giménez D see Diez-Quevedo C
- Giner P see Diez-Quevedo C
- Gitlin MJ, Mintz J, Sokolski K, Hammen C, Altshuler LL. Subsyndromal depressive symptoms after symptomatic recovery from mania are associated with delayed functional recovery. May 692–697
- Glaesmer H see Timpano KR
- Glatt SJ see Waxmonsky JG
- Glick ID, Correll CU, Altamura AC, Marder SR, Csernansky JG, Weiden PJ, Leucht S, Davis JM. Mid-term and long-term efficacy and effectiveness of antipsychotic medications for schizophrenia: a data-driven, personalized clinical approach. Dec 1616–1627
- Glick RM see Andreescu C
- Gobburu J see Laughren TP
- Goff DC, Hill M, Freudenreich O. Treatment adherence in schizophrenia and schizoaffective disorder. Apr e13
- Goldberg JF. Antidepressant use and risk for suicide attempts in bipolar disorder [letter with reply]. Dec 1697
- Goldberg JF see Brooks JO III
- Goldberg TE see Gilbert AM
- Goldblatt MJ. In memory of Jonathon O. Cole [letter]. June 874
- Goldman D see Roy A
- Goldmann E see Calabrese JR
- Goldstein BI see Axelson DA
- Goldstein MZ. Review of Fletcher-Janzen E: *The Neuropsychology of Women*. Feb 264–265
- Goldstein RB see Pickering RP
- Goldstein TR see Axelson DA
- Golinelli D see Stein MB
- Gollan JK see Trivedi MH
- González DA see Ruggero CJ
- González-Pinto A, Barbeito S, Alonso M, Alberich S, Haidar MK, Vieta E, Tabarés-Seisdedos R, Zorrilla I, González-Pinto MA, López P. Poor long-term prognosis in mixed bipolar patients: 10-year outcomes in the Vitoria Prospective Naturalistic Study in Spain. May 671–676
- González-Pinto MA see González-Pinto A
- Gordon TL see Compton MT
- Gorwood P see Corruble E
- Goto T see Calabrese JR
- Gould NF, McKibben JB, Hall R, Corry NH, Amoyal NA, Mason ST, McCann UD, Fauerbach JA. Peritraumatic heart rate and posttraumatic stress disorder in patients with severe burns. Apr 539–547
- Goulding SM see Compton MT
- Grandi S, Sirri L, Tossani E, Fava GA. Psychological characterization of demoralization in the setting of heart transplantation. May 648–654
- Grann M see Jones RM
- Grannemann BD see Trivedi MH
- Grant BF see Comer JS; Pickering RP
- Greenhill LL see Hong HJ
- Greer TL see Trivedi MH
- Greil W see Stübner S
- Greist JH. Review of Marks IM, Cavanagh K, Gega L: *Hands-On Help: Computer-Aided Psychotherapy*. June 876–877
- Grillon C see Cornwell BR
- Grilo CM see Yen S
- Grohmann R see Stübner S
- Gründer G see Paulzen M
- Guarnaccia C see Bradley B
- Guelfi JD see Brecht S
- Gundaya DM see Crisanti AS
- Gunderson JG see Yen S
- Gupta S see Gurrera RJ
- Gurrera RJ, Caroff SN, Cohen A, Carroll BT, DeRoos F, Francis A, Frucht S, Gupta S, Levenson JL, Mahmood A, Mann SC, Policastro MA, Rosebush PI, Rosenberg H, Sachdev PS, Trollor JN, Velamoor VR, Watson CB, Wilkinson JR. International consensus study of neuroleptic malignant syndrome diagnostic criteria using the Delphi method. Sept 1222–1228
- Gurtovaya O see Sachs GS
- Ha K see Frye MA
- Häfner S see Baghai TC
- Hagerman RJ see Bourgeois JA
- Haidar MK see González-Pinto A
- Hakko H see Tchoukhine E
- Hall R see Gould NF
- Hamann J, Mendel R, Reiter S, Cohen R, Bühner M, Schebitz M, Diplich D, Kissling W, Berthele A. Why do some patients with schizophrenia want to be engaged in medical decision making and others do not? Dec 1636–1643
- Hammen C see Gitlin MJ
- Hampel H see Buerger K; Frodl T
- Handley R see Mondelli V
- Hanna B see Berk M
- Hansson O see Buerger K
- Harding KJK, Rush AJ, Arbuckle M, Trivedi MH, Pincus HA. Measurement-based care in psychiatric practice: a policy framework for implementation. Aug 1136–1143
- Harkavy-Friedman JM see Hong HJ
- Hartmann O see Buerger K
- Hasin DS see Comer JS; Pickering RP
- Hausner L, Damian M, Sartorius A, Frölich L. Efficacy and cognitive side effects of electroconvulsive therapy (ECT) in depressed elderly inpatients with coexisting mild cognitive impairment or dementia. Jan 91–97
- Heckers S. Review of Freedman R: *The Madness Within Us: Schizophrenia as a Neuronal Process*. July 1020
- Hellemann G see Suri R
- Heller R see Cornwell BR
- Hellqvist Å see Weisler RH
- Helsel JC see Sit D
- Henderson DC see Fan X
- Henderson KL see Fortney JC
- Henigsberg N see Uher R
- Henin A see Biederman J
- Henley SS see Trivedi MH
- Hepgul N see Mondelli V
- Hernandez R see Lertxundi U
- Herrmann N see Swardfager W
- Herzog DB see Lawson EA
- Hessl D see Bourgeois JA
- Heuser I see Gaebel W
- Hibbeln JR see Lewis MD
- Hill M see Goff DC
- Hirschfeld RMA. Review of Ketter TA (ed): *Handbook of Diagnosis and Treatment of Bipolar Disorders*. June 875–876
- Hoffman VP see Fan X
- Hoge EA see Pollack MH
- Hollander E see Berlin HA
- Hong HJ, Kim YS, Jon D-I, Soek JH, Hong N, Harkavy-Friedman JM, Miller AM, Greenhill LL. Mental health and extracurricular education in Korean first graders: a school-based cross-sectional study. June 861–868
- Hong N see Hong HJ

- Hope S see Steen NE
Hopwood CJ see Yen S
Horwitz SM see Frazier TW
Hösli I see Wirz-Justice A
Houck PR see Andreescu C
Howe AM see Boaz TL; Van Dorn RA
Hua LL, Wilens TE, Martelon M, Wong P, Wozniak J, Biederman J. Psychosocial functioning, familiarity, and psychiatric comorbidity in bipolar youth with and without psychotic features. Mar 397–405
Huang B see Pickering RP
Huang H see Fava M
Hudson PR see Lepping P
Huerta-Ramos E see Usall J
Huff W see Gaebel W
Hummel J, Westphal S, Weber-Hamann B, Gilles M, Lederbogen F, Angermeier T, Luley C, Deuschle M, Kopf D. Serum lipoproteins improve after successful pharmacologic antidepressant treatment: a randomized open-label prospective trial. July 885–891
Hung HMJ see Laughren TP
Hunt JJ see Topor DR
Hunter-Lavin C see Lepping P
Huppert JD see Nacasch N
Husain MM see Trivedi MH; Wall CA
Hyun DY see Lewis MD
Ice KS see Sachs GS
Ilgen MA see Brower KJ
Iniesta R see Usall J
Iosifescu DV see Fava M
Iovieno N, Tedeschi E, Bentley KH, Evins AE, Papakostas GI. Antidepressants for major depressive disorder and dysthymic disorder in patients with comorbid alcohol use disorders: a meta-analysis of placebo-controlled randomized trials. Aug 1144–1151
Iovieno N see Desseilles M; Tedeschini E
Ives JA see Davidson JRT
Iyengar S see Vitiello B
Jackson JS see Boyd RC
Jamhour NJ see Barbee JG
Janicak PG see Wall CA
Jayathilake K see Meltzer HY
Jazbec S see Wirz-Justice A
Jeavons S see Berk M
Jenike MA see Berlin HA
Joe S see Boyd RC
Joffe G see Tchoukhine E
Johnson E see Kemp DE
Johnson JE see Lewis MD
Jon D-I see Hong HJ
Jonas WB see Davidson JRT
Jones RM, Lichtenstein P, Grann M, Långström N, Fazel S. Alcohol use disorders in schizophrenia: a national cohort study of 12,653 patients. June 775–779
Joseph DI. Review of Clarkin JB, Fonagy P, Gabbard GO (eds): *Psychodynamic Psychotherapy for Personality Disorders: A Clinical Handbook*. Nov 1561–1562
Kahn RS see Daalman K; Volavka J
Kajdasz DK see Khan A
Kallenberg G see Zisook S
Kamen L see Marcus RN
Kanba S see Frye MA
Kane JM. Addressing side effects from antipsychotic treatment in schizophrenia. Feb e07
Kane JM. Improving treatment adherence in patients with schizophrenia. Sept e28
Kane JM. Lurasidone: a clinical overview. Suppl 1, 24–28
Kane JM. Performance improvement CME: schizoaffective disorder. July e23
Kane JM. Recent advances in treatments for schizophrenia [introduction]. Suppl 1, 3
Kane JM. Transitioning from acute to long-term treatment in schizophrenia. Mar e10
Kane JM, Correll CU. Performance improvement CME: managing schizophrenia. Oct e31
Kane JM, Mackle M, Snow-Adami L, Zhao J, Szegedi A, Panagides J. Randomized placebo-controlled trial of asenapine for the prevention of relapse of schizophrenia after long-term treatment. Mar 349–355
Kane JM, Potkin SG, Daniel DG, Buckley PF. Double-blind, randomized study comparing the efficacy and safety of sertindole and risperidone in patients with treatment-resistant schizophrenia. Feb 194–204
Kane JM see Athanasiou MC; Correll CU; Gallego JA; Manu P
Kapczinski F, Frey BN, Vieta E. Sleep and circadian rhythm disturbances in bipolar disorder: an urgent need for objective assessment and systematic follow-up [letter]. May 724–725
Kapur N see Oude Voshaar RC
Kapur S see Agid O; Remington G; Sparshatt A
Karayal ON, Anway SD, Batzar E, Vanderburg DG. Assessments of suicidality in double-blind, placebo-controlled trials of ziprasidone. Mar 367–375
Kaslow NJ see Compton MT
Kasuba B see Sachs GS
Kato T see Frye MA
Katsuki F see Watanabe N
Katz C, Yaseen ZS, Mojtabai R, Cohen LJ, Galyner II. Panic as an independent risk factor for suicide attempt in depressive illness: findings from the National Epidemiological Survey on Alcohol and Related Conditions (NESARC). Dec 1628–1635
Katz F see Berk M
Katz LY see Pagura J
Kaur I see Bourgeois JA
Kawamura C see Watanabe N
Keefe RSE see Caroff SN
Kegeles LS see Rodriguez CI
Keller MB see Leon AC; Vitiello B
Kelley D see Signorovitch J
Kelly D see Yung AR
Kemp DE, Johnson E, Wang WV, Tohen M, Calabrese JR. Clinical utility of early improvement to predict response or remission in acute mania: focus on olanzapine and risperidone. Sept 1236–1241
Kemp DE see Gao K; Muzina DJ
Kennard B see Vitiello B
Keshaviah A see Timpano KR
Ketter TA. Strategies for the early recognition of bipolar disorder. July e22
Ketter TA see Brooks JO III
Khalife S see Muzina DJ
Khalsa H-MK see Salvatore P
Khan A, Cutler AJ, Kajdasz DK, Gallipoli S, Athanasiou M, Robinson DS, Whalen H, Reed CR. Randomized, double-blind, placebo-controlled, 8-week study of vilazodone, a serotonergic agent for the treatment of major depressive disorder. Apr 441–447
Khan A see Weisler RH
Khan BK see Woolley JD
Khin NA, Chen Y-F, Yang Y, Yang P, Laughren TP. Exploratory analyses of efficacy data from major depressive disorder trials submitted to the US Food and Drug Administration in support of new drug applications. Apr 464–472. Correction, June 874
Khin NA, Chen Y-F, Yang Y, Yang P, Laughren TP. Reply to Shiovitz TM: Failure rate and “professional subjects” in clinical trials of major depressive disorder [letter]. Sept 1284–1285
Kidolezi Y see Signorovitch J
Kim JB see Woo J-M
Kim J-I see Lee MS
Kim JJ see Soeteman DI
Kim NS see Rottman BM
Kim YS see Hong HJ
King P. Bipolar disorder self-assessment. May e16
King P. 2011 ICBD conference coverage: practical applications of new research in bipolar disorder. Nov e34
Kinkead B see Bonne O
Kinley DJ, Walker JR, Mackenzie CS, Sareen J. Panic attacks and panic disorder in a population-based sample of active Canadian military personnel. Jan 66–74
Kirner-Veselinovic A see Paulzen M
Kirshner HS. Review of Hurley RA, Taber KH (eds): *Windows to the Brain: Insights From Neuroimaging*. Jan 117
Kiss A see Swardfager W
Kissling W see Hamann J
Kivimäki M see Nabi H
Kleban M. Review of Grant JE, Potenza MN (eds): *Young Adult Mental Health*. June 875
Klibanski A see Lawson EA
Klimek V see Laughren TP
Klimke A see Gaebel W
Klingberg S see Gaebel W
Klöppel S see van Elst LT
Kohlmann K see Berk M
Komarov H see Woo J-M
Kontos N. Review of Ghaemi SN: *The Rise and Fall of the Biopsychosocial Model: Reconciling Art and Science in Psychiatry*. Sept 1287–1288
Koorengel KM see Bergink V
Köpcke W see Gaebel W
Kopf D see Hummel J
Koran LM see Berlin HA
Kotov R see Ruggero CJ
Koutsouleris N see Frodl T
Kowatch RA see Axelson DA; Frazier TW
Kozel FA see Wall CA
Kraemer HC. Another point of view: superiority, noninferiority, and the role of active comparators [commentary]. Oct 1350–1352
Kratovich CJ see Correll CU

- Kraus JE see Carpenter DJ
 Krishnan-Sarin S see Liu TC
 Kroenke K see Löwe B
 Krogh J, Nordentoft M, Sterne JAC, Lawlor DA. Effect of exercise in clinically depressed adults: systematic review and meta-analysis of randomized controlled trials. Apr 529–538
 Kryzhanovskaya L see Zanarini MC
 Kung S, Allen JD. Patients and clinicians report higher-than-average satisfaction with psychiatric genotyping for depressed inpatients [letter]. Feb 262–263
 Kuo C-J, Tsai S-Y, Liao Y-T, Conwell Y, Lin S-K, Chang C-L, Chen C-C, Chen WJ. Risk and protective factors for suicide among patients with methamphetamine dependence: a nested case-control study. Apr 487–493
 Kupka R see Bergink V
 Kurian BT see Trivedi MH
 Kushner SA see Bergink V
 Labad J, Alonso P, Segalàs C, Real E, Menchón JM. Reproductive hormone sensitivity and obsessive-compulsive disorder: are there differences in the genetic predisposition between symptom dimensions? [letter] Mar 417–418
 Lambregtse-van den Berg MP see Bergink V
 Lamers F, van Oppen P, Comijs HC, Smit JH, Spinhoven P, van Balkom AJLM, Nolen WA, Zitman FG, Beekman ATF, Penninx BWHJ. Comorbidity patterns of anxiety and depressive disorders in a large cohort study: the Netherlands Study of Depression and Anxiety (NESDA). Mar 341–348
 Lancôt KL see Swardfager W
 Lang AJ see Stein MB
 Långström N see Jones RM
 Lardinois M see Lataster J
 Larsson S see Steen NE
 Lataster J, van Os J, de Haan L, Thewissen V, Bak M, Lataster T, Lardinois M, Delespaul PAEG, Myin-Germeys I. Emotional experience and estimates of D₂ receptor occupancy in psychotic patients treated with haloperidol, risperidone, or olanzapine: an experience sampling study. Oct 1397–1404
 Lataster T see Lataster J
 Laughren TP, Gobburu J, Temple RJ, Unger EF, Bhattaram A, Dinh PV, Fossom L, Hung HMJ, Klimek V, Lee JE, Levin RL, Lindberg CY, Mathis M, Rosloff BN, Wang S-J, Wang Y, Yang P, Yu B, Zhang H, Zhang L, Zineh I. Vilazodone: clinical basis for the US Food and Drug Administration's approval of a new antidepressant. Sept 1166–1173
 Laughren TP see Khin NA
 Laursen TM, Munk-Olsen T, Mortensen PB, Abel KM, Appleby L, Webb RT. Filicide in offspring of parents with severe psychiatric disorders: a population-based cohort study of child homicide. May 698–703
 Lawlor DA see Krogh J
 Lawson A see Signorovitch J
 Lawson EA, Donoho DA, Blum JI, Meenaghan EM, Misra M, Herzog DB, Sluss PM, Miller KK, Klibanski A. Decreased nocturnal oxytocin levels in anorexia nervosa are associated with low bone mineral density and fat mass. Nov 1546–1551
 Layton ME. Review of Roll JM, Rawson RA, Ling W, Shoptaw S (eds): *Methamphetamine Addiction: From Basic Science to Treatment*. Mar 420
 Lebowitz B see Zisook S
 Lederbogen F see Hummel J
 Lee JE see Laughren TP
 Lee MS, Kim J-I, Ernst E. Massage therapy for children with autism spectrum disorders: a systematic review. Mar 406–411
 Le Gall D see Richard-Devantoy S
 Leiner AS see Compton MT
 Lemke M see Gabel W
 Lencz T see Athanasiou MC
 Leon AC. Comparative effectiveness clinical trials in psychiatry: superiority, noninferiority, and the role of active comparators. Oct 1344–1349
 Leon AC. Evolution of psychopharmacology trial design and analysis: six decades in the making. Mar 331–340
 Leon AC. Reply to Siris SG: Searching for serendipity [letter]. Aug 1157
 Leon AC. Two clinical trial designs to examine personalized treatments for psychiatric disorders [commentary]. May 593–597
 Leon AC, Solomon DA, Li C, Fiedorowicz JG, Coryell WH, Endicott J. Reply to Goldberg JF: Antidepressant use and risk for suicide attempts in bipolar disorder [letter]. Dec 1697
 Leon AC, Solomon DA, Li C, Fiedorowicz JG, Coryell WH, Endicott J, Keller MB. Antidepressants and risks of suicide and suicide attempts: a 27-year observational study. May 580–586
 Leon AC see Nierenberg AA
 Lepping P, Delieu J, Mellor R, Williams JHH, Hudson PR, Hunter-Lavin C. Antipsychotic medication and oxidative cell stress: a systematic review. Mar 273–285
 Lerner V see Ritsner MS
 Lertxundi U, Sanchez P, Hernandez R, Elizagarate E. Case of agranulocytosis secondary to rechallenge with clozapine following severe neutropenia during previous therapy [Case Report]. Dec 1659
 Lesem MD see Allen MH
 Lespérance F, Frasure-Smith N, St-André E, Turecki G, Lespérance P, Wisniewski SR. Efficacy of omega-3 supplementation for major depression: a randomized controlled trial. Aug 1054–1062
 Lespérance P see Lespérance F
 Lesser IM see Zisook S
 Lesser ML see Gallego JA
 Leucht S see Glick ID
 Levenson JL see Gurrera RJ
 Levin RL see Laughren TP
 Levkovitz Y, Tedeschini E, Papakostas GI. Efficacy of antidepressants for dysthymia: a meta-analysis of placebo-controlled randomized trials. Apr 509–514
 Levkovitz Y see Tedeschini E
 Lewis MD, Hibbeln JR, Johnson JE, Lin YH, Hyun DY, Loewke JD. Suicide deaths of active-duty US military and omega-3 fatty-acid status: a case-control comparison. Dec 1585–1590
 Li C see Leon AC
 Liang K see Chou K-L
 Liao Y-T see Kuo C-J
 Liberzon I see Calabrese JR
 Libiger J see Volavka J
 Lichtenstein P see Jones RM
 Lieberman JA see Addington DE; Caroff SN
 Lifshitz M see George DT
 Liguori GM see Topor DR
 Lin C-C see Bai YM
 Lin D see Zanarini MC
 Lin S-K see Kuo C-J
 Lin YH see Lewis MD
 Lindberg CY see Laughren TP
 Linn J see Frodl T
 Lionetti TA see George DT
 Liu EY see Fan X
 Liu S-M see Comer JS
 Liu TC, Desai RA, Krishnan-Sarin S, Cavallo DA, Potenza MN. Problematic Internet use and health in adolescents: data from a high school survey in Connecticut. June 836–845
 Loewke JD see Lewis MD
 Lokuge S, Frey BN, Foster JA, Soares CN, Steiner M. Depression in women: windows of vulnerability and new insights into the link between estrogen and serotonin [commentary]. Nov e1563–e1569
 Lomax JW. Review of Young-Bruehl E, Dunbar C: *One Hundred Years of Psychoanalysis, a Timeline: 1900–2000*. Apr 571
 López P see González-Pinto A
 Lops JD see Correll CU
 Lorberg B see Saricicek A
 Lorentzen S see Steen NE
 Lövås K see Steen NE
 Löwe B, Kroenke K, Spitzer RL, Williams JBW, Mussell M, Rose M, Wingenfeld K, Sauer N, Spitzer C. Trauma exposure and posttraumatic stress disorder in primary care patients: cross-sectional criterion standard study. Mar 304–312
 Löwe B see Terfehr K
 Lowenhaupt EA see Topor DR
 Luckenbaugh DA see Bonne O
 Luley C see Hummel J
 Luther JF see Sit D; Trivedi MH; Zisook S
 Lydiard B see Fava M
 Lynch F see Vitiello B
 Lynn DJ. Review of Starcevic V: *Anxiety Disorders in Adults: A Clinical Guide, 2nd ed*. Sept 1286–1287
 Mackenzie CS see Chou K-L; Kinley DJ
 Mackle M see Kane JM
 MacQueen GM see Sidor MM
 Maercker A see Schnyder U
 Maggini C see Salvatore P
 Mahmood A see Gurrera RJ
 Maier W see Gabel W
 Makhinson M, Tsuang J. Review of Alanen YO, de Chavez MG, Silver A-LS, Martindale B (eds): *Psychotherapeutic Approaches to Schizophrenic Psychoses: Past, Present, and Future*. Apr 570
 Malhi GS see Berk M
 Malhotra AK see Athanasiou MC; Correll CU; Gilbert AM
 Maloney K see Saricicek A
 Man S-L see Petersen I

- Mancini C see Van Ameringen M
 Manji HK see Bonne O
 Mankoski R see Marcus RN
 Mann JJ see Dervic K; Sublette ME; Woo J-M
 Mann S see Remington G
 Mann SC see Gurrera RJ
 Manning JS. Selecting appropriate treatment for patients who are nonresponsive to initial therapy. Aug e27
 Manos G see Marcus RN
 Manu P, Kane JM, Correll CU. Sudden deaths in psychiatric patients. July 936–941
 Manu P see Correll CU
 Mar M see Ritsner MS
 March JS see Correll CU
 Marchand S see Normand E
 Marcus RN, Owen R, Manos G, Mankoski R, Kamen L, McQuade RD, Carson WH, Findling RL. Safety and tolerability of aripiprazole for irritability in pediatric patients with autistic disorder: a 52-week, open-label, multicenter study. Sept 1270–1276
 Marcus SC see Olfson M
 Marder SR see Glick ID
 Marechal ES see Brecht S
 Markowitz JC see Yen S
 Marmot MG see Nabi H
 Martelon M see Hua LL
 Martinez J see Zimmerman M
 Martín-Santos R see Diez-Quevedo C
 Marx MS see Cohen-Mansfield J
 Marzolini S see Swardfager W
 Masnou H see Diez-Quevedo C
 Mason ST see Gould NF
 Mathew SJ see Murrough JW
 Mathis M see Laughren TP
 Mayes TL see Vitiello B
 Mazet P see Gerardin P
 McCammon RJ see Brower KJ
 McCann UD see Gould NF
 McCormack J see Gallego JA
 McCracken JT see Vitiello B
 McElroy SL see Frye MA
 McEvoy JP see Addington DE; Caroff SN
 McGlashan TH see Yen S
 McGorry PD see Yung AR
 McGuffin P see Uher R
 McIntyre RS. Implementing guideline-based strategies to avoid relapse and recurrence in depression. Nov e35
 McIntyre RS. Long-term treatment of bipolar disorder in adults. Feb e06
 McIntyre RS, Wagner KD. Performance improvement CME: long-term treatment of bipolar disorder. Mar e09
 McKhann GM see Reiman EM
 McKibben JB see Gould NF
 McQuade RD see Marcus RN
 Meenaghan EM see Lawson EA
 Meerman AMMA see Soeteman DI
 Meisenzahl E see Frodl T
 Melle I see Steen NE
 Mellor R see Lepping P
 Meltzer HY, Bonaccorso S, Bobo WV, Chen Y, Jayathilake K. 12-Month randomized, open-label study of the metabolic effects of olanzapine and risperidone in psychotic patients: influence of valproic acid augmentation. Dec 1602–1610
 Menchón JM see Labad J
 Mendel R see Hamann J
 Mendez MF. Pathological stealing in dementia: poor response to SSRI medications [letter]. Mar 418–419
 Mendlewicz J see Uher R
 Merlo LJ see Stone AM
 Methlie P see Steen NE
 Michalopoulos L see Boyd RC
 Miguel EC see Torres AR
 Miklowitz DJ see Brooks JO III
 Milaneschi Y see Vogelzangs N
 Miller AM see Hong HJ
 Miller BL see Woolley JD
 Miller DD see Caroff SN
 Miller KK see Lawson EA
 Minthorn L see Buerger K
 Mintz J see Gitlin MJ
 Miodownik C see Ritsner MS
 Miorelli A see Mondelli V
 Mischoulon D. Impact of omega-3 fatty acids on depressive disorders and suicidality: can we reconcile 2 studies with seemingly contradictory results? [commentary] Dec 1574–1576
 Mischoulon D see Chen JA; Desseilles M; Fava M
 Misra M see Lawson EA
 Mittal D, Fortney JC, Pyne JM, Wetherell JL. Predictors of persistence of comorbid generalized anxiety disorder among veterans with major depressive disorder. Nov 1445–1451
 Mittal D see Fortney JC
 Mohamed S see Addington DE
 Mojtabai R see Katz C; Pagura J
 Möller H-J see Buerger K; Frodl T; Gaebel W
 Mondelli V, Cattaneo A, Murri MB, Di Forti M, Handley R, Hepgul N, Miorelli A, Navari S, Papadopoulos AS, Aitchison KJ, Morgan C, Murray RM, Dazzan P, Pariante CM. Stress and inflammation reduce brain-derived neurotrophic factor expression in first-episode psychosis: a pathway to smaller hippocampal volume. Dec 1677–1684
 Moore C see Carpenter DJ
 Moreira ALR see Van Meter AR
 Morenz B. Review of Simon RI, Gold LH (eds): *The American Psychiatric Publishing Textbook of Forensic Psychiatry, 2nd ed.* Dec 1700
 Morey LC see Yen S
 Morgan C see Mondelli V
 Morillas RM see Diez-Quevedo C
 Mork E see Steen NE
 Morokuma I see Watanabe N
 Morris DW see Trivedi MH; Zisook S
 Mors O see Uher R
 Mortensen PB see Laursen TM
 Moscardino U, Scrimin S, Capello F, Altoè G. Are Beslan's children learning to cope? a 3-year prospective study of youths exposed to terrorism. Sept 1277–1283
 Moshier SJ see Pollack MH
 Mosyagin I see Athanasiou MC
 Muhtz C see Terfehr K
 Müller J see Schnyder U
 Mulsant BH see Andreescu C
 Munib A see Berk M
 Munk-Jørgensen P see Nielsen J
 Munk-Olsen T see Laursen TM
 Munzar P see Allen MH
 Muralidharan A see Saricicek A
 Murphy E see Oude Voshaar RC
 Murray RM see Mondelli V
 Murri MB see Mondelli V
 Murrough JW, Perez AM, Mathew SJ, Charney DS. Case of sustained remission following an acute course of ketamine in treatment-resistant depression [letter]. Mar 414–415
 Murthy NK see Woolley JD
 Mussell M see Löwe B
 Muzina DJ, Gao K, Kemp DE, Khalife S, Ganocy SJ, Chan PK, Serrano MB, Conroy CM, Calabrese JR. Acute efficacy of divalproex sodium versus placebo in mood stabilizer-naïve bipolar I or II depression: a double-blind, randomized, placebo-controlled trial. June 813–819
 Myin-Germeys I see Lataster J
 Nabi H, Kivimäki M, Empaña J-P, Sabia S, Britton A, Marmot MG, Shipley MJ, Singh-Manoux A. Combined effects of depressive symptoms and resting heart rate on mortality: the Whitehall II Prospective Cohort Study. Sept 1199–1206
 Nacasch N, Foa EB, Huppert JD, Tzur D, Fostick L, Dinstein Y, Polliack M, Zohar J. Prolonged exposure therapy for combat- and terror-related posttraumatic stress disorder: a randomized control comparison with treatment as usual. Sept 1174–1180
 Naidoo N see Nuevo R
 Nakata A. Work hours, sleep sufficiency, and prevalence of depression among full-time employees: a community-based cross-sectional study. May 605–614
 Napolitano B see Gallego JA
 Navari S see Mondelli V
 Navinés R see Diez-Quevedo C
 Nazareth I see Petersen I
 Neijber A see Weisler RH
 Nelson B see Yung AR
 Nelson JC see Tedeschi E
 Neumeister A see Bonne O
 Newcorn JH. Risks and benefits of available treatments for adult ADHD. Mar e12
 Newcorn JH see Adler LA
 Ng F see Berk M
 Nguyen DV see Bourgeois JA
 Nielsen J, Munk-Jørgensen P, Skadhede S, Correll CU. Determinants of poor dental care in patients with schizophrenia: a historical, prospective database study. Feb 140–143
 Nierenberg AA. Alternatives to antidepressants in treating acute bipolar depression. Jan e03
 Nierenberg AA. Reply to Teboul E: Keeping 'em honest: the current crisis of confidence in antidepressants [letter]. July 1015–1016
 Nierenberg AA, Leon AC, Price LH, Shelton RC, Trivedi MH. Crisis of confidence: antidepressant risk versus benefit. Mar e11
 Nierenberg AA, Leon AC, Price LH, Shelton RC, Trivedi MH. Current crisis of confidence in antidepressants [commentary]. Jan 27–33
 Nierenberg AA see Peters AT; Posternak MA; Zisook S
 Nizard J see Gerardin P
 Nolen WA see Lamers F; Weisler RH

- Nomura K see Suzuki T
 Nordentoft M see Krogh J
 Normand E, Potvin S, Gaumont I, Cloutier G, Corbin J-F, Marchand S. Pain inhibition is deficient in chronic widespread pain but normal in major depressive disorder. Feb 219–224
 Norton J see Chaudieu I
 Nuevo R, Chatterji S, Fraguas D, Verdes E, Naidoo N, Arango C, Ayuso-Mateos JL. Increased risk of diabetes mellitus among persons with psychotic symptoms: results from the WHO World Health Survey. Dec 1592–1599
 Nurnberg HG. Randomized controlled trials of olanzapine treatment of borderline personality disorder: two similar studies with different results [commentary]. Oct 1363–1365
 Nutt DJ. Highlights of the International Consensus Statement on Major Depressive Disorder. June e21
 Nyer M see Desseilles M
 Ochoa S see Usall J
 Oh PI see Swardfager W
 Ohmann C see Gaebel W
 Olsson M, Marcus SC, Doshi JA. Reply to van den Noort M: Schizophrenia-related outpatient treatment of Medicaid-financed patients after hospital discharge [letter]. Jan 113–114
 Olsson M see Comer JS
 Olié J-P see Richard-Devantoy S
 Oller S see Portella MJ
 Onorato M see Vitiello B
 Oquendo MA see Dervic K
 O'Reardon JP see Cranstacho P
 Otmar R see Berk M
 Otte C see Terfehr K
 Oude Voshaar RC, Cooper J, Murphy E, Steeg S, Kapur N, Purandare NB. First episode of self-harm in older age: a report from the 10-year prospective Manchester Self-Harm project. June 737–743
 Oudega ML, van Exel E, Wattjes MP, Comijs HC, Scheltens P, Barkhof F, Eikelenboom P, de Craen AJM, Beekman ATF, Stek ML. White matter hyperintensities, medial temporal lobe atrophy, cortical atrophy, and response to electroconvulsive therapy in severely depressed elderly patients. Jan 104–112
 Owen R see Marcus RN
 Owens MJ see Bonne O
 Özderdem A see Frye MA
 Padrino SL. Review of Morgan C, Bhugra D (eds): *Principles of Social Psychiatry*, 2nd ed. Nov 1560–1561
 Pagura J, Katz LY, Mojtabai R, Druss BG, Cox B, Sareen J. Antidepressant use in the absence of common mental disorders in the general population. Apr 494–501
 Pallanti S see Berlin HA
 Panagides J see Kane JM
 PanYuen H see Yung AR
 Papadopoulos AS see Mondelli V
 Papakostas GI see Chen JA; Iovieno N; Levkovitz Y; Tedeschi E
 Parens E see Gillihan SJ
 Pariante CM see Mondelli V
 Paris J. Dimensional diagnosis and *DSM-5* [commentary]. Oct 1340
 Patel MX see Sparshatt A
 Patkar AA see Paulozzi LJ
 Patterson B see Van Ameringen M
 Patwa HS see Volpe D
 Paulozzi LJ, Weisler RH, Patkar AA. National epidemic of unintentional prescription opioid overdose deaths: how physicians can help control it [commentary]. May 589–592
 Paulsson B see Weisler RH
 Paulzen M, Tauber SC, Kirner-Veselinovic A, Gründer G. Cytochrome P450 2D6 polymorphism and its impact on decision-making in psychopharmacotherapy: finding the right way in an ultrarapid metabolizing patient [Case Report]. Nov 1465–1467
 Peele R, Siddiqi H. Review of Blackman JS: *Get the Diagnosis Right: Assessment and Treatment Selection for Mental Disorders*. Sept 1287
 Penninx BWJH see Lamers F; Vogelzangs N; Wiersma JE
 Perel JM see Sit D
 Perez AM see Murrrough JW
 Pérez V see Portella MJ
 Peritogiannis V, Tsouli S. Emerging role of atypical antipsychotics in the treatment of tardive dyskinesia induced by other atypical antipsychotics [letter with reply]. July 1016
 Perlis ML see Watanabe N
 Peters AT, Nierenberg AA. Stepping back to step forward: lessons from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD) [ASCP Corner]. Oct 1429–1431
 Petersen I, Gilbert RE, Evans SJW, Man S-L, Nazareth I. Pregnancy as a major determinant for discontinuation of antidepressants: an analysis of data from The Health Improvement Network. July 979–985
 Petersen RC see Reiman EM
 Petrovic A see Uher R
 Petti TA. Review of Whitaker R: *Anatomy of an Epidemic: Magic Bullets, Psychiatric Drugs, and the Astonishing Rise of Mental Illness in America*. Mar 421
 Petty CR see Biederman J
 Pfennig A see Strech D
 Phifer J see Bradley B
 Phillips G see Signorovitch J
 Phillips LJ see Yung AR
 Phillips MJ see George DT
 Pickering RP, Goldstein RB, Hasin DS, Blanco C, Smith SM, Huang B, Pulay AJ, Ruan WJ, Saha TD, Stinson FS, Dawson DA, Chou SP, Grant BF. Temporal relationships between overweight and obesity and *DSM-IV* substance use, mood, and anxiety disorders: results from a prospective study, the National Epidemiologic Survey on Alcohol and Related Conditions. Nov 1494–1502
 Pierz KA see Athanasiou MC
 Pies R see Zisook S
 Pikalov A see Weisler RH
 Pincus HA see Harding KJK
 Pine DS see Cornwell BR
 Pintov L see Ritsner MS
 Pitman RK see Gilbertson MW
 Pittman B see Saricicek A
 Planas R see Diez-Quevedo C
 Podhorna J see Brecht S
 Policastro MA see Gurrera RJ
 Pollack MH, Hoge EA, Worthington JJ, Moshier SJ, Wechsler RS, Brandes M, Simon NM. Eszopiclone for the treatment of posttraumatic stress disorder and associated insomnia: a randomized, double-blind, placebo-controlled trial. July 892–897
 Polliack M see Nacasch N
 Pollock BG see Gerretsen P
 Polo AJ, Alegria M, Chen C-N, Blanco C. Prevalence and comorbidity of social anxiety disorder among United States Latinos: a retrospective analysis of data from 2 national surveys. Aug 1096–1105
 Porta G see Vitiello B
 Portella MJ, Ballesteros J, Artigas F, Pérez V. Reply to Terao T: Can pindolol really enhance antidepressant effect? [letter] Nov 1558
 Portella MJ, de Diego-Adelino J, Ballesteros J, Puigdemont D, Oller S, Santos B, Álvarez E, Artigas F, Pérez V. Can we really accelerate and enhance the selective serotonin reuptake inhibitor antidepressant effect? a randomized clinical trial and a meta-analysis of pindolol in nonresistant depression. July 962–969
 Posternak MA, Baer L, Nierenberg AA, Fava M. Response rates to fluoxetine in subjects who initially show no improvement. July 949–954
 Postolache TT see Woo J-M
 Potenza MN see Liu TC
 Potkin SG. Asenapine: a clinical overview. Suppl 1, 14–18
 Potkin SG see Kane JM
 Potts AJ see Fan X
 Potvin S see Normand E
 Prakash R. Review of McKeon: *Suicidal Behavior*. Feb 264
 Prescott M see Calabrese JR
 Pretel J see Diez-Quevedo C
 Price LH see Nierenberg AA
 Puigdemont D see Portella MJ
 Pulay AJ see Pickering RP
 Purandare NB see Oude Voshaar RC
 Putkonen H see Tchoukhine E
 Pyne JM see Fortney JC; Mittal D
 Qin P see Woo J-M
 Raidma M see Tchoukhine E
 Rajewska-Rager A see Uher R
 Rakofsky JJ, Dunlop BW. Treating nonspecific anxiety and anxiety disorders in patients with bipolar disorder: a review. Jan 81–90
 Ramos-Cerqueira ATA see Torres AR
 Randall M. Review of Glassman A, Maj M, Sartorius N (eds): *Depression and Heart Disease*. Aug 1158–1159
 Rankin KP see Woolley JD
 Rapaport MH see Freeman MP
 Räsänen P see Tchoukhine E
 Rasmussen KG. Do antidepressants really beget more depressive episodes? [letter with reply] Jan 115–116

- Ratner Y see Ritsner MS
 Rauer S see van Elst LT
 Rawlings RR see George DT
 Real E see Labad J
 Reed CR see Athanasiou MC; Khan A
 Reiman EM, McKhann GM, Albert MS, Sperling RA, Petersen RC, Blacker D. Alzheimer's disease: implications of the updated diagnostic and research criteria. Sept 1190–1196
 Reiman EM, McKhann GM, Albert MS, Sperling RA, Petersen RC, Blacker D. Clinical impact of updated diagnostic and research criteria for Alzheimer's disease. Dec e37
 Reimherr FW see Barbee JG
 Reiter S see Hamann J
 Remington G, Seeman P, Feingold A, Mann S, Shammi C, Kapur S. "Extended" antipsychotic dosing in the maintenance treatment of schizophrenia: a double-blind, placebo-controlled trial. Aug 1042–1048
 Remington G see Agid O
 Resnick PJ see Friedman SH
 Ressler KJ see Bradley B
 Reynolds CF III see Zisook S
 Richard-Devantoy S, Anweiler C, Le Gall D, Garré J-B, Olié J-P, Beaudet O. Cognitive inhibition in suicidal depressed elderly: a case-control pilot study [letter]. June 871–872
 Riecher-Rössler A see Wirz-Justice A
 Riedel M see Gaebel W
 Rief W see Timpano KR
 Riesbeck M see Gaebel W
 Rietschel M see Uher R
 Riggio S see Caroff SN
 Rijnierse P see Soeteman DI
 Ritchie K see Chaudieu I
 Ritsner MS, Miodownik C, Ratner Y, Shleifer T, Mar M, Pintov L, Lerner V. L-theanine relieves positive, activation, and anxiety symptoms in patients with schizophrenia and schizoaffective disorder: an 8-week, randomized, double-blind, placebo-controlled, 2-center study. Jan 34–42
 Roberts MW. Review of Kay J, Schwartz V (eds): *Mental Health Care in the College Community*. Nov 1560
 Robinson DE see Fortney JC
 Robinson DG see Gallego JA
 Robinson DS see Khan A
 Robst J see Boaz TL
 Roca M see Usall J
 Rodriguez Cl, Kegeles LS, Flood P, Simpson HB. Rapid resolution of obsessions after an infusion of intravenous ketamine in a patient with treatment-resistant obsessive-compulsive disorder [letter]. Apr 567–569
 Rofman ES. Review of Gask L, Lester H, Kendrick T, Pevler (eds): *Primary Care Mental Health*. July 1018
 Rogers CA see Woo J-M
 Rose M see Löwe B
 Rose RD see Stein MB
 Rosebush PI see Gurrera RJ
 Rosenberg H see Gurrera RJ
 Rosenheck RA see Addington DE; Caroff SN
 Rosloff BN see Laughren TP
 Ross ML see Yung AR
 Ross R see Allen MH
 Rossus BV see Soeteman DI
 Roth T see Fava M; Surman CBH
 Rottman BM, Kim NS, Ahn W-k, Sanislow CA. Can personality disorder experts recognize DSM-IV personality disorders from five-factor model descriptions of patient cases? May 630–639
 Roy A, Roy M, Goldman D. Childhood trauma and depressive symptoms in type 1 diabetes. Aug 1049–1053
 Roy M see Roy A
 Roy-Byrne PP see Stein MB
 Ruan WJ see Pickering RP
 Rubinstein D see Shemesh E
 Ruf B see Saricicek A
 Ruggero CJ, Kotov R, Carlson GA, Tanenberg-Karant M, González DA, Bromet EJ. Diagnostic consistency of major depression with psychosis across 10 years. Sept 1207–1213
 Rupprecht R see Baghai TC
 Rush AJ see Harding KJK; Zisook S
 Ryan ND see Axelson DA; Frazier TW; Vitiello B
 Sabia S see Nabi H
 Sachdev PS see Gurrera RJ
 Sachs GS, Dupuy JM, Wittmann CW. Pharmacologic treatment of bipolar disorder. May 704–715
 Sachs GS, Ice KS, Chappell PB, Schwartz JH, Gurtovaya O, Vanderburg DG, Kasuba B. Efficacy and safety of adjunctive oral ziprasidone for acute treatment of depression in patients with bipolar I disorder: a randomized, double-blind, placebo-controlled trial. Oct 1413–1422
 Sadhu JM, Beresin EV. Review of Parens H: *Handling Children's Aggression Constructively: Toward Taming Human Destructiveness*. Oct 1432
 Saha TD see Pickering RP
 Sajeew G see Agid O
 Saleem M see Swardfager W
 Salisbury BA see Athanasiou MC
 Salomon RM. Review of David AS, Fleminger S, Kopelman MD, Lovestone S, Mellers JDC: *Lishman's Organic Psychiatry, 4th ed*. Jan 118–119
 Saltz BL see Caroff SN
 Salvail FR see Crisanti AS
 Salvatore P, Baldessarini RJ, Tohen M, Khalsa H-MK, Sanchez-Toledo JP, Zarate CA Jr, Vieta E, Maggini C. McLean-Harvard International First-Episode Project: two-year stability of ICD-10 diagnoses in 500 first-episode psychotic disorder patients. Feb 183–193
 Salzman C. Review of Hertzman M, Adler L: *Clinical Trials in Psychopharmacology: A Better Brain*. Apr 571
 Sampson SM see Wall CA
 Sanacora G see Saricicek A
 Sanchez P see Lertxundi U
 Sanchez-Toledo JP see Salvatore P
 Sanislow CA see Rottman BM; Yen S
 Santini AM see Brecht S
 Santos B see Portella MJ
 Santra M see Shemesh E
 Sareen J see Chou K-L; Kinley DJ; Pagura J
 Saricicek A, Maloney K, Muralidharan A, Ruf B, Blumberg HP, Sanacora G, Lorberg B, Pittman B, Bhagwagar Z. Levetiracetam in the management of bipolar depression: a randomized, double-blind, placebo-controlled trial. June 744–750
 Sartorius A see Hausner L
 Sasaki M see Watanabe N
 Sauer H see Gaebel W
 Sauer N see Löwe B
 Schaefer K see Fava M
 Schapkaitz I see Berk M
 Schebitz M see Hamann J
 Scheltens P see Oudega ML
 Scheuerecker J see Frodl T
 Schlechte JA see Calarge CA
 Schlosser N see Terfehr K
 Schmitt A see Gaebel W
 Schneider A see Bourgeois JA
 Schnyder U, Müller J, Maercker A, Wittmann L. Brief eclectic psychotherapy for PTSD: a randomized controlled trial [letter]. Apr 564–566
 Schoepf V see Frodl T
 Schooler NR. Jonathan O. Cole, MD (1925–2009): innovator in clinical psychopharmacology and of the ECDEU/NCDEU tradition. Mar 286–287
 Schüle C see Baghai TC
 Schulz SC see Zanarini MC
 Schwartz JH see Sachs GS
 Scrimin S see Moscardino U
 Seeman P see Remington G
 Segalàs C see Labad J
 Seritan AL see Bourgeois JA
 Serrano MB see Calabrese JR; Muzina DJ
 Serrano-Blanco A see Usall J
 Sevy SM see Gallego JA
 Shammi C see Remington G
 Shapira NA see Berlin HA
 Sharma B see Fan X
 Shaya Y see Gilbert AM
 Shea MT see Yen S
 Shear MK see Zisook S
 Sheehan DV see Fava M
 Shelton JS. Cosmetics count [Publisher's Note]. Sept 1165
 Shelton JS. JCP 2011: our world keeps improving [Publisher's Note]. June 736
 Shelton JS. NCDEU Festschrift—celebrating 50 years [Publisher's Note]. May 579
 Shelton RC, Trivedi MH. Challenges and algorithm-guided treatment in major depressive disorder. Apr e14
 Shelton RC, Trivedi MH. Moderators of antidepressant response in major depression. Oct e32
 Shelton RC, Trivedi MH. Performance improvement CME: algorithms and EMRs in depression. Sept e29
 Shelton RC, Trivedi MH. Using algorithms and computerized decision support systems to treat major depression. Dec e36
 Shelton RC, Trivedi MH. Using moderator-based algorithms and electronic medical records to achieve optimal outcomes in depression. July e24
 Shelton RC see Barbee JG; Fava M; Nierenberg AA
 Shemesh E, Annunziato RA, Weatherley BD, Cotter G, Feaganes JR, Santra M, Yehuda R, Rubinstein D. Randomized controlled trial of the safety and promise of cognitive-behavioral therapy using imaginal exposure in patients with posttraumatic stress disorder resulting from cardiovascular illness. Feb 168–174

- Sherbourne CD see Stein MB
 Shimodera S see Watanabe N
 Shiovitz AM see Shiovitz TM
 Shiovitz TM, Zarrow ME, Shiovitz AM, Bystritsky AM.
 Failure rate and “professional subjects” in
 clinical trials of major depressive disorder
 [letter with reply]. Sept 1284
 Shipley MJ see Nabi H
 Shirley E see Calabrese JR
 Shleifer T see Ritsner MS
 Shore JH. Review of Stern TA, Fricchione GL,
 Cassem NH, Jellinek MS, Rosenbaum JF
 (eds): *Massachusetts General Hospital
 Handbook of General Hospital Psychiatry*,
 6th ed. July 1019
 Shrivastava RK see Fava M
 Siddiqi H see Peele R
 Sidor MM, MacQueen GM. Antidepressants for
 the acute treatment of bipolar depression:
 a systematic review and meta-analysis.
 Feb 156–167
 Sidor MM, MacQueen GM. Reply to Cruz N,
 Vieta E: Antidepressants in acute bipolar
 depression: an inconclusive meta-analysis
 [letter]. Mar 416
 Signorovitch J, Birnbaum H, Ben-Hamadi R, Yu AP,
 Kidolezi Y, Kelley D, Phillips G, Lawson A, Ball DE.
 Increased olanzapine discontinuation and
 health care resource utilization following
 a Medicaid policy change. June 787–794
 Sim LA see Wall CA
 Simmons MB see Yung AR
 Simon NM see Pollack MH; Zisook S
 Simpson HB see Rodriguez CI
 Singh-Manoux A see Nabi H
 Siris SG. Searching for serendipity [letter with
 reply]. Aug 1156–1157
 Sirri I see Grandi S
 Sit D, Perel JM, Wisniewski SR, Helsel JC, Luther JF,
 Wisner KL. Mother-infant antidepressant
 concentrations, maternal depression, and
 perinatal events. July 994–1001
 Sizemore J see Calabrese JR
 Skadhede S see Nielsen J
 Skodol AE see Yen S
 Slembariski R see Calabrese JR
 Sluss PM see Lawson EA
 Smit JH see Lamers F
 Smith EG, Craig TJ, Ganoczy D, Walters HM,
 Valenstein M. Treatment of veterans with
 depression who died by suicide: timing
 and quality of care at last Veterans Health
 Administration visit. May 622–629
 Smith SM see Pickering RP
 Snow-Adami L see Kane JM
 Soares CN see Lokuge S
 Soek JH see Hong JH
 Soeteman DI, Verheul R, Meerman AMMA,
 Ziegler U, Rossum BV, Delimon J, Rijniense P,
 Thunnissen M, Busschbach JJV, Kim JJ.
 Cost-effectiveness of psychotherapy
 for cluster C personality disorders:
 a decision-analytic model in the
 Netherlands. Jan 51–59
 Sokolski K see Gitlin MJ
 Solà R see Diez-Quevedo C
 Solomon DA see Leon AC
 Soltmann B see Strech D
 Sommer IEC see Daalman K
 Sparhawk R. In bipolar disorder beyond
 10 weeks of treatment, the term
antidepressants is a misnomer [letter].
 June 871
 Sparshatt A, Taylor D, Patel MX, Kapur S.
 Relationship between daily dose, plasma
 concentrations, dopamine receptor
 occupancy, and clinical response to
 quetiapine: a review. Aug 1108–1123
 Sperling RA see Reiman EM
 Spero DE see George DT
 Spinhoven P see Lamers F
 Spirito A see Topor DR; Vitiello B
 Spitzer C see Löwe B; Terfehr K
 Spitzer RL see Löwe B
 Spyker DA see Allen MH
 Stafford L, Berk M. Use of statins after a
 cardiac intervention is associated with
 reduced risk of subsequent depression:
 proof of concept for the inflammatory
 and oxidative hypotheses of depression?
 Sept 1229–1235
 Stagno SJ. Review of Peteet JR, Lu FG,
 Narrow WE (eds): *Religious and Spiritual
 Issues in Psychiatric Diagnosis: A Research
 Agenda for DSM-V*. Dec 1699–1700
 St-André E see Lespérance F
 Stecker T see Fortney JC
 Steeg S see Oude Voshaar RC
 Steen NE, Methlie P, Lorentzen S, Hope S, Barrett EA,
 Larsson S, Mork E, Almås B, Løvås K, Agartz I,
 Melle I, Berg JP, Andreassen OA. Increased
 systemic cortisol metabolism in patients
 with schizophrenia and bipolar disorder:
 a mechanism for increased stress
 vulnerability? Nov 1515–1521
 Stein MB, Roy-Byrne PP, Craske MG, Campbell-Sills L,
 Lang AJ, Golinelli D, Rose RD, Bystritsky A,
 Sullivan G, Sherbourne CD. Quality of and
 patient satisfaction with primary health
 care for anxiety disorders. July 970–976
 Steiner M see Lokuge S
 Stek ML see Oudega ML
 Stenberg J-H see Tchoukhine E
 Sterne JAC see Krogh J
 Stewart JW see Barbee JG
 Stieglitz R-D see Wirz-Justice A
 Stinson FS see Pickering RP
 Stone AM, Merlo LJ. Attitudes of college
 students toward mental illness stigma and
 the misuse of psychiatric medications.
 Feb 134–139
 Stowe ZN see Suri R
 Strain JJ. Review of Gabbard GO: *Long-Term
 Psychodynamic Psychotherapy: A Basic
 Text*, 2nd ed. Aug 1158
 Strakowski SM. Review of Yatham LN,
 Maj M (eds): *Bipolar Disorder: Clinical
 and Neurobiological Foundations*.
 Oct 1433–1434
 Strech D, Soltmann B, Weikert B, Bauer M, Pfennig A.
 Quality of reporting of randomized
 controlled trials of pharmacologic
 treatment of bipolar disorders: a systematic
 review. Sept 1214–1221
 Streltzer J. Review of Ruiz P, Primm A:
*Disparities in Psychiatric Care: Clinical and
 Cross-Cultural Perspectives*. Feb 264
 Strober MA see Vitiello B
 Stroup TS see Addington DE; Caroff SN
 Stübner S, Grohmann R, Greil W. Reply to
 Baldessarini RJ: Suicidal risk during
 antidepressant treatment [letter]. May 722
 Su T-P see Bai YM
 Sublette ME, Ellis SP, Geant AL, Mann JJ.
 Meta-analysis of the effects of
 eicosapentaenoic acid (EPA) in clinical
 trials in depression. Dec 1577–1584
 Sudak DM. Review of Wright JH,
 Turkington D, Kingdon DG, Basco MR:
*Cognitive-Behavior Therapy for Severe
 Mental Illness: An Illustrated Guide*.
 Mar 420–421
 Sudak HS. Review of Hollander E, Zohar J,
 Sirovataka PJ, Regier DA (eds):
*Obsessive-Compulsive Spectrum Disorders:
 Refining the Research Agenda for DSM-V*.
 Sept 1286
 Suddath R see Vitiello B
 Sullivan G see Stein MB
 Sunderajan P see Trivedi MH
 Suri R, Hellemann G, Stowe ZN, Cohen LS, Aquino A,
 Altschuler LL. Prospective, naturalistic,
 blinded study of early neurobehavioral
 outcomes for infants following prenatal
 antidepressant exposure. July 1002–1007
 Surman CBH, Roth T. Impact of stimulant
 pharmacotherapy on sleep quality: post
 hoc analyses of 2 large, double-blind,
 randomized, placebo-controlled trials.
 July 903–908
 Suzuki T. Metabolic syndrome in inpatients
 treated with clozapine [letter with reply].
 June 872–873
 Suzuki T, Nomura K, Watanabe K. Risks of
 intermittent antipsychotic treatment in
 schizophrenia [letter with reply]. Jan 114
 Swardfager W, Herrmann N, Marzolini S, Saleem M,
 Farber SB, Kiss A, Oh PI, Lanctôt KL. Major
 depressive disorder predicts completion,
 adherence, and outcomes in cardiac
 rehabilitation: a prospective cohort study
 of 195 patients with coronary artery
 disease. Sept 1181–1188
 Swartz HA, Thase ME. Pharmacotherapy for the
 treatment of acute bipolar II depression:
 current evidence. Mar 356–366
 Swartz MS see Addington DE; Caroff SN
 Swenson LP see Topor DR
 Szegeidi A see Kane JM
 Tabarés-Seisdedos R see González-Pinto A
 Takala P see Tchoukhine E
 Tamburrino M see Calabrese JR
 Tan Y-L see Zhang W-F
 Tanaka Y see Zanarini MC
 Tandon R. Antipsychotics in the treatment of
 schizophrenia: an overview. Suppl 1, 4–8
 Tanenberg-Karant M see Ruggero CJ
 Tauber SC see Paulzen M
 Taylor D see Sparshatt A
 Tchoukhine E, Takala P, Hakko H, Raidma M,
 Putkonen H, Räsänen P, Terevnikov V,
 Stenberg J-H, Eronen M, Joffe G. Orlistat in
 clozapine- or olanzapine-treated patients
 with overweight or obesity: a 16-week
 open-label extension phase and both
 phases of a randomized controlled trial.
 Mar 326–330
 Teba F see Usall J

- Teboul E.** Keeping 'em honest: the current crisis of confidence in antidepressants [letter with reply]. July 1015
- Tedeschini E, Fava M, Papakostas GI.** Placebo-controlled, antidepressant clinical trials cannot be shortened to less than 4 weeks' duration: a pooled analysis of randomized clinical trials employing a diagnostic odds ratio-based approach. Jan 98–103
- Tedeschini E, Levkovitz Y, Iovieno N, Ameral VE, Nelson JC, Papakostas GI.** Efficacy of antidepressants for late-life depression: a meta-analysis and meta-regression of placebo-controlled randomized trials. Dec 1660–1668
- Tedeschini E see Iovieno N; Levkovitz Y**
- Teipel SJ see Buerger K**
- Temple RJ see Laughren TP**
- Terao T.** Can pindolol really enhance antidepressant effect? [letter with reply] Nov 1558
- Terevnikov V see Tchoukhine E**
- Terfehr K, Wolf OT, Schlosser N, Fernando SC, Otte C, Muhtz C, Beblo T, Driessen M, Spitzer C, Löwe B, Wingenfeld K.** Effects of acute hydrocortisone administration on declarative memory in patients with major depression: a placebo-controlled, double-blind crossover study. Dec 1644–1650
- Terman M see Wirz-Justice A**
- Thampi A see Yung AR**
- Thase ME.** Role of neurobiologic processes in symptoms of depression. Feb e08
- Thase ME.** Treatment-resistant depression: prevalence, risk factors, and treatment strategies. May e18
- Thase ME see Brooks JO III; Carpenter DJ; Cristancho P; Swartz HA**
- Thein K see Cohen-Mansfield J**
- Thewissen V see Lataster J**
- Thompson AD see Yung AR**
- Thompson PM see Barbee JG**
- Thompson TR see Barbee JG**
- Thunissen M see Soeteman DI**
- Timpano KR, Exner C, Glaesmer H, Rief W, Keshaviah A, Brähler E, Wilhelm S.** Epidemiology of the proposed *DSM-5* hoarding disorder: exploration of the acquisition specifier, associated features, and distress. June 780–786
- Tohen M see Kemp DE; Salvatore P**
- Topor DR, Swenson LP, Liguori GM, Spirito A, Lowenhaupt EA, Hunt JI.** Problematic Video Game Use Scale: initial psychometric properties with psychiatrically hospitalized adolescents. Dec 1611–1615
- Tordjman S see Gerardin P**
- Torres AR, Ramos-Cerqueira ATA, Ferrão YA, Fontenelle LF, do Rosário MC, Miguel EC.** Suicidality in obsessive-compulsive disorder: prevalence and relation to symptom dimensions and comorbid conditions. Jan 17–26
- Tossani E see Grandi S**
- Tran QV see Weisler RH**
- Trial 144 Study Investigators see Weisler RH**
- Triffleman EG see Crisanti AS**
- Trivedi MH, Greer TL, Church TS, Carmody TJ, Grannemann BD, Galper DI, Dunn AL, Earnest CP, Sunderajan P, Henley SS, Blair SN.** Exercise as an augmentation treatment for nonremitted major depressive disorder: a randomized, parallel dose comparison. May 677–684
- Trivedi MH, Wisniewski SR, Morris DW, Fava M, Gollan JK, Warden D, Nierenberg AA, Gaynes BN, Husain MM, Luther JF, Zisook S, Rush AJ.** Concise Health Risk Tracking Scale: a brief self-report and clinician rating of suicidal risk. June 757–764
- Trivedi MH, Wisniewski SR, Morris DW, Fava M, Kurian BT, Gollan JK, Nierenberg AA, Warden D, Gaynes BN, Luther JF, Rush AJ.** Concise Associated Symptoms Tracking Scale: a brief self-report and clinician rating of symptoms associated with suicidality. June 765–774
- Trivedi MH see Harding KJK; Nierenberg AA; Shelton RC; Weisler RH; Zisook S**
- Trollorc JN see Gurrera RJ**
- Tsai S-Y see Kuo C-J**
- Tsouli S see Peritogiannis V**
- Tsuang J see Makhinson M**
- Turecki G see Lespérance F**
- Turner JB see Comer JS**
- Tzur D see Nacasch N**
- Uher R, Mors O, Rietschel M, Rajewska-Rager A, Petrovic A, Zobel A, Henigsberg N, Mendlewicz J, Aitchison KJ, Farmer A, McGuffin P.** Early and delayed onset of response to antidepressants in individual trajectories of change during treatment of major depression: a secondary analysis of data from the Genome-Based Therapeutic Drugs for Depression (GENDEP) Study. Nov 1478–1484
- Umhau JC see George DT**
- Unger EF see Laughren TP**
- Usall J, Huerta-Ramos E, Iniesta R, Cobo J, Araya S, Roca M, Serrano-Blanco A, Teba F, Ochoa S.** Raloxifene as an adjunctive treatment for postmenopausal women with schizophrenia: a double-blind, randomized, placebo-controlled trial. Nov 1552–1557
- Uspenskaya O see Buerger K**
- Vaiva G see Chaudieu I**
- Valenstein M see Brower KJ; Smith EG**
- Van Ameringen M, Mancini C, Patterson B.** Impact of changing diagnostic criteria in posttraumatic stress disorder in a Canadian epidemiologic sample. Aug 1034–1041
- van Balkom AJLM see Lamers F**
- van den Noort M, Bosch P.** Schizophrenia-related outpatient treatment of Medicaid-financed patients after hospital discharge [letter with reply]. Jan 113
- Vanderburg DG see Karayal ON; Sachs GS**
- van der Does AJW see Wiersma JE**
- Van Dorn RA, Andel R, Boaz TL, Desmarais SL, Chandler K, Becker MA, Howe A.** Risk of arrest in persons with schizophrenia and bipolar disorder in a Florida Medicaid program: the role of atypical antipsychotics, conventional neuroleptics, and routine outpatient behavioral health services. Apr 502–508
- van Elst LT, Klöppel S, Rauer S.** Voltage-gated potassium channel/LGI1 antibody-associated encephalopathy may cause brief psychotic disorder [letter]. May 722–723
- van Exel E see Oudega ML**
- Van Meter AR, Moreira ALR, Youngstrom EA.** Meta-analysis of epidemiologic studies of pediatric bipolar disorder. Sept 1250–1256
- van Oppen P see Lamers F; Wiersma JE**
- van Os J see Lataster J**
- van Schaik DJF see Wiersma JE**
- van Watum PJ.** Review of Kaminer Y, Winters KC (eds): *Clinical Manual of Adolescent Substance Abuse Treatment*. Dec 1700–1701
- Varallo-Bedarida G see Baghai TC**
- Vázquez G see Frye MA**
- Velamoor VR see Gurrera RJ**
- Verdes E see Nuevo R**
- Verheul R see Soeteman DI**
- Vieta E see Cruz N; Frye MA; González-Pinto A; Kapczinski F; Salvatore P**
- Vitiello B, Emslie G, Clarke G, Wagner KD, Asarnow JR, Keller MB, Birmaher B, Ryan ND, Kennard B, Mayes TL, DeBar L, Lynch F, Dickerson J, Strober M, Suddath R, McCracken JT, Spirito A, Onorato M, Zelazny J, Porta G, Iyengar S, Brent DA.** Long-term outcome of adolescent depression initially resistant to selective serotonin reuptake inhibitor treatment: a follow-up study of the TORDIA sample. Mar 388–396
- Vivek S.** Review of Leigh H: *Genes, Memes, Culture, and Mental Illness: Toward an Integrative Model*. Dec 1699
- Vogelzangs N, Beekman ATF, Boelhouwer IG, Bandinelli S, Milaneschi Y, Ferrucci L, Penninx BWJH.** Metabolic depression: a chronic depressive subtype? findings from the InCHIANTI study of older persons. May 598–604
- Volavka J, Czobor P, Derks EM, Bitter I, Libiger J, Kahn RS, Fleischhacker WW, EUFEST Study Group.** Efficacy of antipsychotic drugs against hostility in the European First-Episode Schizophrenia Trial (EUFEST). July 955–961
- Volpe D, Patwa HS.** Review of Weiner WJ, Goetz CG Shin RK, Lewis SL (eds): *Neurology for the Non-Neurologist, 6th ed.* Oct 1432–1433
- von Schacky C see Baghai TC**
- von Wilmsdorff M see Gaebel W**
- Vythilingam M see Bonne O**
- Wagner KD.** Controversial issues in child psychiatry [introduction]. June 835
- Wagner KD.** Impact of mood disorders [introduction]. Mar 376–377
- Wagner KD.** Potpourri of timely topics [introduction]. Sept 1248–1249
- Wagner KD see McIntyre RS; Vitiello B**
- Wakefield JC, First MB.** Treatment outcome for bereavement-excluded depression: results of the study by Corruble et al are not what they seem [letter with reply]. Aug 1155
- Walker EF see Compton MT**
- Walker JR see Kinley DJ**
- Wall CA, Croarkin PE, Sim LA, Husain MM, Janicak PG, Kozel FA, Emslie GJ, Dowd SM, Sampson SM.** Adjunctive use of repetitive transcranial magnetic stimulation in depressed adolescents: a prospective, open pilot study. Sept 1263–1269

- Walsh Z see Yen S
Walters HM see Smith EG
Wang S-J see Laughren TP
Wang WV see Kemp DE
Wang Y see Laughren TP
Wang Z see Gao K
Warden D see Trivedi MH
Waschbusch DA see Waxmonsky JG
Watanabe K see Suzuki T
Watanabe N, Furukawa TA, Shimodera S, Morokuma I, Katsuki F, Fujita H, Sasaki M, Kawamura C, Perlis ML. Brief behavioral therapy for refractory insomnia in residual depression: an assessor-blind, randomized controlled trial. Dec 1651–1658
- Watson CB see Gurrera RJ
Wattjes MP see Oudega ML
Waxmonsky JG, Waschbusch DA, Glatt SJ, Faraone SV. Prediction of placebo response in 2 clinical trials of lisdexamfetamine dimesylate for the treatment of ADHD. Oct 1366–1375
- Weatherley BD see Shemesh E
Webb RT see Laursen TM
Weber-Hamann B see Hummel J
Wechsler RS see Pollack MH
Weiden PJ see Glick ID
Weikert B see Strech D
Weisler RH, Khan A, Trivedi MH, Yang H, Eudicone JM, Pikalov A, Tran QV, Berman RM, Carlson BX. Analysis of suicidality in pooled data from 2 double-blind, placebo-controlled aripiprazole adjunctive therapy trials in major depressive disorder. Apr 548–555
- Weisler RH, Nolen WA, Neijber A, Hellqvist Å, Paulsson B, Trial 144 Study Investigators. Continuation of quetiapine versus switching to placebo or lithium for maintenance treatment of bipolar I disorder (Trial 144: a randomized controlled study). Nov 1452–1464
- Weisler RH see Paulozzi LJ
Weiss PS see Compton MT
Weissman SH. Review of Frankland AG: *The Little Psychotherapy Book: Object Relations in Practice*. Sept 1288
- Wendland J see Gerardin P
Wessel TC see Fava M
Westen D see Bradley B
Westphal S see Hummel J
Wetherell JL see Mittal D
Whalen H see Athanasiou MC; Khan A
Wiersma JE, van Oppen P, van Schaik DJF, van der Does AJW, Beekman ATF, Penninx BWJH. Psychological characteristics of chronic depression: a longitudinal cohort study. Mar 288–294
- Wiesmann M see Frodl T
Wilens TE see Hua LL
Wilhelm S see Timpano KR
Wilkinson JR see Gurrera RJ
- Williams JBW see Löwe B
Williams JHH see Lepping P
Wilson A see Fava M
Wilson K see Calabrese JR
Wingenfeld K see Löwe B; Terfehr K
Wirz-Justice A, Bader A, Frisch U, Stieglitz R-D, Alder J, Bitzer J, Hösl I, Jazbec S, Benedetti F, Terman M, Wisner KL, Riecher-Rössler A. Randomized, double-blind, placebo-controlled study of light therapy for antepartum depression. July 986–993
- Wise TN. Review of Black DW, Andreasen NC: *Introductory Textbook of Psychiatry, 5th ed*. Aug 1159
- Wisner KL see Sit D; Wirz-Justice A
Wisniewski SR see Lespérance F; Sit D; Zisook S
Witte J see Deseilles M
Wittmann CW see Sachs GS
Wittmann L see Schnyder U
Wojnar J see Brower KJ
Wojnar M see Brower KJ
Wolf OT see Terfehr K
Wölwer W see Gaebel W
Wong P see Hua LL
- Woo J-M, Gibbons RD, Qin P, Komarow H, Kim JB, Rogers CA, Mann JJ, Postolache TT. Suicide and prescription rates of intranasal corticosteroids and non-sedating antihistamines for allergic rhinitis: an ecological study. Oct 1423–1428
- Woolley JD, Khan BK, Murthy NK, Miller BL, Rankin KP. Diagnostic challenge of psychiatric symptoms in neurodegenerative disease: rates of and risk factors for prior psychiatric diagnosis in patients with early neurodegenerative disease. Feb 126–133
- Worthington JJ see Pollack MH
Wozniak J see Biederman J; Hua LL
Wu H-R see Zhang W-F
Yager J. Review of Grilo CM, Mitchell JE (eds): *The Treatment of Eating Disorders: A Clinical Handbook*. May 727–728
- Yang H see Weisler RH
Yang P see Khin NA; Laughren TP
Yang Y see Bourgeois JA; Khin NA
Yaseen ZS see Katz C
Yehuda R see Shemesh E
Yen S, Shea MT, Walsh Z, Edelen MO, Hopwood CJ, Markowitz JC, Ansell EB, Morey LC, Grilo CM, Sanislow CA, Skodol AE, Gunderson JG, Zanarini MC, McGlashan TH. Self-harm subscale of the Schedule for Nonadaptive and Adaptive Personality (SNAP): predicting suicide attempts over 8 years of follow-up. Nov 1522–1528
- Yip PSF see Chen Y-Y; Cheng Q
Youn SJ see Chen JA
Young D see Zimmerman M
Youngstrom EA see Axelson DA; Frazier TW; Van Meter AR
- Yu AP see Signorovitch J
Yu B see Laughren TP
Yuan P see Bonne O
Yung AR, Phillips LJ, Nelson B, Francey SM, PanYuen H, Simmons MB, Ross ML, Kelly D, Baker K, Amminger GP, Berger G, Thompson AD, Thampi A, McGorry PD. Randomized controlled trial of interventions for young people at ultra high risk for psychosis: 6-month analysis. Apr 430–440
- Zajacka JM see Fava M
Zanarini MC, Schulz SC, Detke HC, Tanaka Y, Zhao F, Lin D, Deberdt W, Kryzhanovskaya L, Corya S. Dose comparison of olanzapine for the treatment of borderline personality disorder: a 12-week randomized, double-blind, placebo-controlled study. Oct 1353–1362
- Zanarini MC see Yen S
Zarate CA Jr see Salvatore P
Zarrow ME see Shivovitz TM
Zelazny J see Vitiello B
Zhang H see Laughren TP
Zhang L see Laughren TP
Zhang W-F, Tan Y-L, Zhang X-Y, Chan RCK, Wu H-R, Zhou D-F. Extract of *Ginkgo biloba* treatment for tardive dyskinesia in schizophrenia: a randomized, double-blind, placebo-controlled trial. May 615–621
- Zhang X-Y see Zhang W-F
Zhao F see Zanarini MC
Zhao J see Kane JM
Zhou D-F see Zhang W-F
Ziegler U see Soeteman DI
Zimbardo DL see Allen MH
Zimmerman B see Calarge CA
Zimmerman M, Chelminski I, Young D, Dalrymple K, Martinez J. Does *DSM-IV* already capture the dimensional nature of personality disorders? Oct 1333–1339
- Zineh I see Laughren TP
Zipursky RB see Agid O
Zisook S, Lesser IM, Lebowitz B, Rush AJ, Kallenberg G, Wisniewski SR, Nierenberg AA, Fava M, Luther JF, Morris DW, Trivedi MH. Effect of antidepressant medication treatment on suicidal ideation and behavior in a randomized trial: an exploratory report from the Combining Medications to Enhance Depression Outcomes Study. Oct 1322–1332
- Zisook S, Reynolds CF III, Pies R, Simon NM, Lebowitz B, Shear MK. Reply to Clayton PJ: Back to “normal bereavement” [letter]. Feb 260–261
- Zisook S see Trivedi MH
Zitman FG see Lamers F
Zobel A see Uher R
Zohar J see Nacasch N
Zorrilla I see González-Pinto A
Zou W see Athanasiou MC